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Abstract
Known as direct-to-consumer advertising (DTCA), pharmaceutical companies in the
United States are permitted to advertise prescription drugs directly to consumers. The
purpose of this quantitative study was to determine if an association exists between
DTCA and health care-seeking behaviors. The theoretical framework for this study
involved social learning theory, information integration theory, and prospect theory. The
research questions identified if exposure to DTCA (a) is associated with physician office
visits, (b) influences a patient/physician conversation regarding a prescription, (c)
influences requesting a prescription, and (d) has an impact on patients’ ratings of the
overall interaction with the physician. Data were derived from an online survey adapted
from the U.S. Food and Drug Administration. Participants included 235 college-affiliated
adults. Data were analyzed using descriptive statistics and analysis of variance. The
Bonferroni correction was used to control the family-wise Type I error rate. The most
significant findings of this study are that DTCA is associated with patients asking more
questions, having more office visits, and patients having a lower overall health status.
Future researchers should consider a non-college-affiliated sample and the postimplementation impact of the Affordable Care Act. This study helps to address the
community challenges of how DTCA impacts prescription drug use and costs, as well as
patients’ understanding of the associated risks. Having knowledge of the impact of
DTCA can help patients and their communities, employers, and governments make more
informed decisions that will positively impact their health, wellbeing, and prescription
expenses.
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Chapter 1: Introduction to the Study
Background
The number of people taking prescription medications is on the rise. In 1993, the
average number of prescriptions per person annually was seven, compared to 11 in 2000,
and 12.1 in 2011, with West Virginia reaching a high of 19.3 (National Center for Health
Statistics, 2014). In the United States alone, the total annual retail sales for prescription
drugs filled in 2011 was $228 billion (National Center for Health Statistics, 2014). Over
half of all people in the United States take a minimum of one prescription medication
daily, on average (National Center for Health Statistics, 2014). Additionally,
Pharmaceutical Research and Manufacturers of America (PhRMA; 2011) spent $28
million in 2009 lobbying members of Congress (Blumenthal, 2010). Despite safety
concerns for certain prescriptions and the unknown effects of others, people rely on
medications for numerous reasons. There is also concern about drug quality (Tognoni,
Toussaint, Herxheimer, & Schaaber, 2014) and the association between research and
advertising (Koch, Brandenburger, Türpe, & Birringer, 2014; McCarthy, 2014; Sacks et
al., 2014; Sood, Kappe, & Stremersch, 2014). This worldwide drug dependency,
questions about physician reliance and ethical decisions (Graf, Miller, & Nagel, 2014),
and the involvement of medical financial resources (Jofre, 2014; Kmietowicz, 2014) have
all created concerns about how pharmaceutical firms are portraying or marketing their
products to consumers.
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These concerns, at least in part, are centered in whether the quality of direct-toconsumer advertising (DTCA) creates a positive net benefit when compared to ethical,
social, and economic costs (Kesselheim, 2013; Lansing & Vohra, 2013; Lichtenberg,
2011; Rusthoven, 2014). D. Lee and Emmett (2012) found that physicians are concerned
about denying patients’ requests for advertised prescription medications. There is a need
for further comprehensive research of direct-to-consumer marketing (DTCM) and DTCA
to determine whether DTCA stimulates patients to seek prescription drugs that they do
not need (Jureidini, Mintzes, Raven, & Block, 2008; Kulkarni, 2014; McKinlay,
Trachtenberg, Marceau, Katz, & Fischer, 2014; Moore, 2014a).
In this study, I focused on advertising (specifically DTCA) in the overall
marketing field. Hawthorne (2010) claimed that the practice of advertising directly to
consumers was an event that preceded the existence of the U.S. Food and Drug
Administration (FDA). DTCA can be defined as using the lay media as a tool to promote
prescription drug information to the public (Ventola, 2011). Marketing directly to the
consumer is not a new practice. It was common during the 19th century to find phony
medicines advertised in newspapers. These advertisements often claimed that the
advertised medicine had healing abilities. Debates existed even then over the advertising
and the legal and ethical aspects of marketing campaigns aimed at the general public. In
the 1900s, the American Medical Association (AMA) tried to end public advertising by
contacting medical journals and requesting an end to such practices (Hawthorne, 2010).
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Critics during this time period accused the AMA of trying to control the medication
purchasing process for financial gain.
There has been a transition from the traditional approach wherein pharmaceutical
companies targeted physicians to introduce new products and to increase the use of their
products. In the mid-1990s, focus was redirected on the end users of prescription drugs
(Hawthorne, 2010). With pressure from the pharmaceutical industry and other parties, the
FDA, which has been the U.S. regulatory body for prescription medication since 1962,
has changed its position on marketing campaigns aimed directly at consumers
(Hawthorne, 2010). The first DTCA advertisement occurred in 1983, which is when the
FDA requested industry assistance in developing a formal policy. A draft of this guidance
was presented to the FDA in 1997, with the final version issued to the industry in 1999.
The regulations required the inclusion of a brief summary of product in print
advertisements. Possible drug side effects, contraindications, and effectiveness were
required disclosures information for each drug summary.
The United States and New Zealand are the only two countries that allow DTCA.
Many countries have strict prescription requirements; in some countries, physicians must
provide patients with a password to access information on the Internet to a drug
company. DTCA presents its own set of challenges for advertising practitioners due to
the possible harmful impact that medicines can have; however, as a whole, ethics in
advertising is a difficult balance to achieve. Despite these challenges, the practice of
DTCA is a sizeable marketing practice that continues to grow. Pharmaceutical companies
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spend twice as much on advertising as they do on research and development (Tadena,
2010). They also court physicians (Moore, 2014b). The pharmaceutical industry has one
of the highest profit margins of any industry, with the top pharmaceutical companies,
including Pfizer, GlaxoSmithKline, and Bristol-Myers Squibb (Kornfield, Donohue,
Berndt, & Alexander, 2013). As of 2010, Pfizer media spending reached $967.5 million,
with Lipitor as the top advertised drug (Bulik, 2011). Advertisement spending increased
from $700 million in 1996 to $5.4 billion in 2006 (Bulik, 2011). However, the spending
declined by 20% from 2006 to 2010 (Bulik, 2011). The suggested causes for this decline
include a decline in the number of new drugs, a decline in consumer spending, and
consumer skepticism (Bulik, 2011).
Supporters of DTCA list several factors to support the practice, which include the
empowering of consumers with information, public health awareness, and improved
compliance with medication regimens. Those in support of DTCA argue that, by giving
individuals better information, more informed health decisions can be made (Hawthorne,
2010). Providing this information is viewed by some supporters as a right to which each
person is entitled. Also, with DTCA, people are becoming more in tune with their health
condition and there is an overall greater awareness of medical conditions (Hawthorne,
2010). DTCA supporters believe that advertising has resulted in the general public
becoming more comfortable with discussing medical conditions, as well as discussing
such concerns with their physician. Supporters also argue that the final decision to
prescribe a medication still remains with the doctor, but DTCA makes the patient aware
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that there may be other possible treatments (Ahn, Park, & Haley, 2014; Liang & Mackey,
2011). These positions all assume that patients possess adequate understanding and
knowledge to interpret technical information.
There are possible risks associated with taking prescription medications.
Opponents of DTCA claim that DTCA fails to provide accurate information, increases
physician time to correct misconceptions, ignores prevention and focuses on cure, and
increases costs to the health care system (Huh & Shin, 2014). Opponents argue that
advertisements, especially via TV commercials, cannot adequately cover these issues
(Hawthorne, 2010). Additionally, many drug advertisements are the same as
advertisements for basic and harmless other products. Although a physician’s
prescription is still required, DTCA can be a manipulative technique (Huh & Shin, 2014;
Moore, 2013). Hawthorne (2010) suggested that the decision to take medications is not a
simple process; rather, it is one that involves diagnostic tests, family history analysis,
possible interactions, and other important elements. For these reasons the decision to take
a prescription involves the consideration of many factors and exposure to DTCA may or
may not be sufficient alone to make a final decision.
Studies have been conducted on exposure to DTCA for specific diseases. Jureidini
et al. (2008), using a prior study conducted by Block (2007), examined the net social
benefit of DTCA of antidepressants. Block used a DTCA survey and other empirical
research to analyze care-seeking behavior when exposed to antidepressant advertising.
According to Block, the use of advertising of antidepressants leads to a large net benefit.
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However, Block argued that a net benefit would exist even if all people in the United
States were treated with an antidepressant. Jureidini et al. claimed that Block’s model,
which included four steps, was missing a step. In the original study, the four steps
included the following: the number of people exposed to advertising that motivates
treatment, those with clinical depression, those who may or may not have depression but
who receive prescriptions, and those who benefit from drug treatment. The step missing
from Jureidini et al.’s study involved looking at the proportion of people experiencing
harm from the prescription for both those having and not having depression.
The differences in the two DTCA research approaches in studying depression
includes arguments regarding the use of various estimates. Block (2007), using data from
the FDA, the Henry J. Kaiser Family Foundation, and from the U.S. National Ambulatory
Care Survey, estimated that 4.59 million (9.4%) of 48.9 million consultations would have
been stimulated by DTCA in 2000. Additionally, Block estimated that, for the same year,
5.85 million people experienced untreated depression. However, Jureidini et al. (2008)
argued that Block’s estimates were overly high. One example of Block’s overestimate,
according to Juriedini et al., was that the number of untreated people in the United States
was derived from a subset in which there was minimal impairment, which goes against
meeting the diagnostic criteria. Although Jureidini et al. stated that Block’s work
contributed to the DTCA debate, there were some noted weaknesses. Jureidini et al.
concluded that advertising for antidepressants via television is presented in a seductive
manner; however, no bottom line can be drawn on the benefits of DTCA. Mackert et al.
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(2013) stated that DTCA is an educational tool that has benefited the patient by involving
them in the decision making process. A patient may research their condition and the
various available drugs once they are exposed to DTCA. Although physician approval is
needed for a prescription, the patient is no longer relying solely on the physician.
Extensive research on DTCA is limited. However, the FDA Office of Prescription
Drug Promotion (OPDP) has researched and continues to research this topic. Most
studies conducted by the OPDP have been experimental in nature (HHS, 2004). The
survey that was used for the present study was taken from the only research conducted by
the OPDP using this type of research method. As such, the present study added to the
growing body of research in this field.
Statement of the Problem
There are potentially significant adverse public health care consequences posed
by DTCA, such as overuse, cost burden on patients, exploited public policy, and wasted
limited resources. DTCA, or prescription drug advertising, is permitted by the FDA, the
regulating government agency in the United States (HHS, 2004). The FDA attempts to
assure safe drugs for both human and veterinary use. The office within the FDA that
investigates the applied/theoretical issues relating to the communication of risk and
benefit for DTCA and professional promotional prescription drug material is the OPDP.
The pharmaceutical industry is a profitable business. Additionally, DTCA has
grown exponentially from less than $1 billion in 1996 (Bulik, 2011) to $4.2 billion in
2008 (Greene & Kesselheim, 2010; Macias, Lewis, & Baek, 2010), to $11 billion in 2010
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(Ghosh & Ghosh, 2010). Pharmaceutical firms record more than $300 billion in sales
revenue annually (Spurling et al., 2010). Provider targeting promotion has reached $36.1
billion (Kornfield et al., 2013) and improper drug use costs U.S. employers more than
$276 billion (Conlon et al., 2012) in lost productivity, accidents, and health care costs.
Additionally, developing countries are now spending 20-60% of their health budgets on
prescription drugs, and governments tend to pay above-market rates, straining already
limited governmental resources (Greene & Kesselheim, 2010). Finally, several
pharmaceutical firms have paid settlements of $2.3 and $3 billion when confronted with
allegations of inappropriate off-label marketing (Kesselheim, Mello, & Studdert, 2011;
Matthews, 2013; Outterson, 2012). The examples of the above settlements and the overall
possibility for large profits suggest the need for regulations and supervision.
The 340B Drug Discount Program was created by Congress in 1992 to provide
significant discounts to organizations providing care for the indigent. Despite good
intentions, the program has resulted in abuses that victimize the patients that the program
was designed to help. Through an unrealized contractual loophole, health care
organizations were able to increase their profit margins, while not passing on the
expected discounts to indigent patients (Bress, 2014; J. Lee, 2013; Pollak, 2013). From a
public policy perspective, this loophole provides an incentive to entice patients,
especially the indigent who tend to be less educated (Kaushal, 2014; Robbins, Stillwell,
Wilson, & Fitzgerald, 2012), to request prescriptions they have seen in advertisements.
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Marketing of prescription drugs is distinctive in that potential risks to the patient
in the marketing of these drugs are required to be disclosed by the FDA. However,
patient perceptions about these advertisements may be distorted, given their often limited
clinical understanding. In many cases, patients are either not afforded adequate time and
or lack the ability to fully understand the risks and benefits of prescription drugs (Bishop
& Salmon, 2013; Herbst, Hannah, & Allan, 2013). Not fully understanding the side
effects, complications, and the cumulative interactions of prescription drugs presents a
potential risk of injury or even death for patients. Additionally, although physician
assistance is required, exposure to these types of advertisements may encourage
medication-seeking behaviors (Bishop & Salmon, 2013; Bradford & Kleit, 2011;
Callaghan, Laraway, Snycerski, & McGee, 2013; D. Lee & Emmett, 2012). In this study,
I used the social learning theory, information integration theory, and prospect theory to
examine consumer behavior as it relates to DTCA of prescription drugs.
Purpose of the Study
The purpose of this quantitative study was to determine the possible association
between DTCA and health care-seeking behaviors and to explore patient perspectives on
DTCA relative to patients’ overall health care experience. If there is a link between the
advertising component of marketing campaigns and health care-seeking behavior, an
overuse of unnecessary medications and a subsequent decline in health status, wasted
resources, exploited health policy, and cost burden could result for patients, employers,
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and governments. FDA guidance and regulations, federal and state health care policy, and
patient interaction with health care professionals are all impacted by DTCA.
Researchers remain unclear about the impact of DTCA on patient behavior
(Callaghan et al., 2013; Lee-Wingate & Xie, 2013; Mukherjee, Limbu, & Wanasika,
2013; Niederdeppe, Byrne, Avery, & Cantor, 2013). This study will help to fill this gap
and provide a deeper understanding of the possible association between DTCA and
patient behavior. Additionally, given the concerns and risks associated with inappropriate
prescription drug use (Mackey & Liang, 2013), an additional purpose of this study is to
provide information for more socially responsible decision making for both patient and
doctor.
Research Questions and Hypotheses
The following research questions were addressed in detail and acted as a catalyst
for this study:
1.

What is the relationship between direct-to-consumer advertising (DTCA)
and physician office visits?

2.

What is the relationship between direct-to-consumer advertising (DTCA)
and patients asking for a prescription?

These questions were researched through two hypotheses. The independent
variable in this study was patient exposure. The dependent variables were physician
office visits and asking for a prescription. Each hypothesis was tested to determine which
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independent variables were significantly associated with patient health care-seeking
behaviors. Hypothesis 1 is related to physician office visits and exposure to DTCA:
H10: There is no relationship between patient exposure to DTCA and subsequent
physician office visits.
H1a: There is a direct association between patient exposure to DTCA and
subsequent physician office visits.
Hypothesis 2 is related to requests for a specific prescription medication and exposure to
DTCA:
H20: There is no relationship between patient exposure to DTCA and a patient
asking subsequently for a corresponding prescription drug.
H2a: There is a direct association between patient exposure to DTCA and a
patient asking subsequently for a corresponding prescription drug.
Model components are depicted in Table 1. Chapter 3 provides a detailed
description of the research methods and techniques used to analyze the hypotheses.
Table 1.
Components of the Model
Hypotheses

Independent variables

Dependent variables

1

Patient exposure

Physician office visits

2

Patient exposure

Asking for a prescription
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Theoretical Base
In this study, the theoretical framework consisted of social learning theory,
information integration theory, and prospect theory to examine consumer behavior as it
relates to DTCA of prescription drugs. Bandura’s (1971) social learning theory includes
elements of conditioning and learning with cognitive aspects, while extending internal
factors to explain behavior. Social learning theorists attempt to clarify behavior by
examining environmental influences (Thorpe & Olson, 1990). Reciprocal determinism is
the term used to explain the interactional process that applies to the shaping of behavior
(Bandura, 1971). The interactions between the environment, the person, and the behavior
have an equal impact on or influence of one another. Such interactions can include
situations in which a person makes self-adjustments or when a person talks to himself or
herself. Reciprocal determinism is important in explaining how a person learns by
observing or modeling.
There are various theories that attempt to explain how learning occurs. Bandura
(1971) argued that the majority of learning is gained through a person’s direct
experiences or secondhand observations. Thorpe and Olson (1990) presented three effects
of learning: observational learning effects, inhibitory and disinhibitory effects, and
response facilitation effects. When a person uses previously learned responses in new
situations, this behavior demonstrates observational learning. In inhibitory and
disinhibitory effects, a person can repeat or not repeat an observed behavior of a model
based upon the consequences observed. If the observer is discouraged from engaging in
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the behavior, an inhibitory effect occurs. With disinhibitory effect, the observer is
encouraged by the observed behavior. Response facilitation effects can be described as
observing a behavior that is defined as acceptable and following four steps in the
modeling process.
In the learning process the observer first observes the model and then retains the
information. The observer then compiles all of the observed information together and
then, in the final steps, the actual modeling of the behavior occurs (Thorpe & Olsen,
1990). Modeling can take on many forms in addition to an actual live model or
observation. Modeling can also take place from observing media, television, and so on.
This type of modeling is known as symbolic modeling (Thorpe & Olsen, 1990). Also,
covert modeling can take place in which the observer imagines observing a model
(Thorpe & Olsen, 1990). According to Bandura (1969), imitating an observed behavior
does not have to immediately occur following the observation. A person may not be
aware of the observed images or the imitation of the observed behavior.
Studies have been conducted on DTCA and modeling. One example of this is
when Welch Cline and Young (2004) conducted a content analysis based on Bandura’s
(1971) social learning theory. The purpose of the Welch Cline and Young study was to
identify features of DTCA that may function as modeling. Visual cues were examined as
vicarious motivators. According to Bandura’s social learning theory, when a behavior is
observed, the possible observed rewards can become motivators. Specifically in DTCA
cures, happy or healthy product users serve as motivators. The Welch Cline and Young
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study consisted of reviewing advertisements in 18 popular magazines for a 2-year period,
from January 1998 to December 1999. Four research questions were developed:
1.

What percentage of direct-to-consumer print advertisements depicted
models?

2.

What are the demographic characteristics of models depicted in direct-toconsumer print advertisements?

3.

What are the nature and frequency of identity rewards offered in direct-toconsumer print advertisements via visual cues?

4.

What are the natures and frequency of relational rewards offered in directto-consumer print advertisements via visual cues, respectively?

Welch Cline and Young (2004) indicated that more than 80% of the advertisements
contained models and 35.7% included inanimate objects. Welch Cline and Young also
indicated the use of either male or female models in advertisements; 33.3% of the ads
used more female models than men. Advertisements with only African Americans,
Hispanic Americans, or Asian Americans were few: 14.2%, 1.1%, and .5%, respectively.
In 91.8% of the advertisements, people who appeared healthy were depicted. Welch
Cline and Young concluded that changes in health care behavior might be triggered by
DTCA. Consumers are often exposed to visual models with positive features, such as
being active and friendly.
An example of another study focused on the nonmedical use of prescription
drugs. Mui, Sales, and Murphy (2014) conducted a study of inappropriate prescription
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drug use by individuals between the ages of 18 and 25 in the San Francisco Bay area.
Social learning theory was used as a framework to understand the learned and imitated
aspects of deviant behavior. Mui et al. found that through differential association,
imitation, definitions, and differential reinforcement, social context can set the stage for
behavior. Nonmedical drug use is popular among young adults and social learning theory
provides support for the framework for understanding the initiation of nonmedical drug
use. Also, from the 120 total participants in the Mui et al study, 73.3% were currently
attending college.
In comparison differences between social learning theory and information
integration theory. According to social learning theory (Bandura, 1971), behavior is
examined as related to environmental influences, whereas information integration
theorists (Anderson, 2014) examine how various sources of information are integrated
internally by a person. Information integration theory was proposed by Anderson (2014)
and was developed around four concepts: stimulus integration, stimulus valuation,
cognitive algebra, and functional measurement. The fundamental concept in integration
theory is that the way in which a person thinks or behaves depends upon multiple stimuli
acting in cooperation with one another. Anderson’s (2014) four concepts interlock when
physical stimuli impose upon a person. Integration function combines the transformed
psychological stimuli into an implicit response, which is then externalized using the
response function. A person uses simple algebraic rules on the stimulus information
before producing a response (Anderson, 2014).
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Prospect theory is used to examine how a person makes decisions. Developed by
Kahneman and Tversky (1979), prospect theorists attempt to describe decisions that are
made in which a person makes a choice among alternatives when risk is involved. There
are two phases in the decision process: editing and evaluation. During the editing phase,
there is an initial analysis of the possible alternatives and the outcomes for a decision.
This stage is followed by an evaluation of the alternatives, with the highest value choice
selected. During the narrowing of alternatives, distinguishing features are evaluated in
terms of gains or losses, while similar components are disregarded, demonstrating the
isolation effect (Nickerson, 2012).
Nature of the Study
In this study, I used a quantitative approach to determine the association between
DTCA and health care-seeking behaviors. Survey data were collected using a virtual
bulletin board accessible to students who attended an online university and
SurveyMonkey. Various research studies are regularly available on the virtual bulletin
board. Students who show an interest can participate in a research study after completing
an online informed consent form prior to the survey.
The collected data were analyzed and compared to data available in the public
domain from documents obtained by the U.S. Department of Health and Human Services
(HHS; 2004), of which the FDA is an agency. Specific reviews of prescription drug
advertisements and promotional labeling are regularly performed by the FDA OPDP. The
original research design used surveys in which participants were asked approximately 65
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questions and the variables were measured based upon the responses. The results of the
FDA study were published in 2004; however, the data were collected in 1999 and 2002
from telephone surveys.
In this study, I used the same 2004 survey instrument used by the HHS, but via
online survey. The survey instrument is located on a public domain. The data were
analyzed using analysis of variance (ANOVA), which were employed to test the
hypotheses of this study. With each analysis, statistical significance and predictive value
were assessed as applicable. Statistical Package for the Social Sciences (SPSS), Version
21, was used for all data analyses, and statistical significance was assessed at the p < 0.05
level. Finally, the predictive power of the two equations was compared to determine the
predictive value of DTCA. Further analytical details are provided in Chapter 3, with
results presented in Chapter 4.
Definitions of Terms
The following technical terms are used in this study:
Direct-to-consumer advertising (DTCA): A component of direct-to consumer
marketing that involves the practice of presenting advertising material directly to the
possible user rather than to the physician (Rollins & Perri, 2014).
Direct-to-consumer marketing (DTCM): A method of marketing that links
consumers and suppliers together through comprehensive, systematic, market-based
planning, managing, promoting, and advertising of products directly to consumers
(Rollins & Perri, 2014).
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Foreign consumer culture positioning (FCCP): A marketing position associated
with a particular foreign culture (Alden, Steenkamp, & Batra, 1999).
Food and Drug Administration Amendments Act (FDAAA; 2007): A law that
added provisions to the Federal Food, Drug, and Cosmetic Act, which gives the FDA
authority to regulate drugs and other products.
Global consumer culture positioning (GCCP): An alternative approach to brand
positioning that is designed for international marketing. GCCP involves sharing symbols
that denote membership in a global consumer segment (Alden et al., 1999).
Local consumer culture positioning (LCCP): An approach to marketing that is
associated with a particular local culture (Alden et al., 1999).
Patient exposure: A patient’s recall of seeing or hearing any advertisement for
prescription drugs (HHS, 2004).
Physician office visit: A face-to-face, care-driven interaction with a physician,
physician assistant, or nurse practitioner working for a physician (HHS, 2004)
Voluntary simplicity: The source of personal satisfaction and happiness coming
from nonmaterial aspects of life (Shaw & Newholm, 2002).
Assumptions
In conducting this study, I assumed that all participants responded truthfully to the
survey and that all participants had access to the Internet or a computer. Additionally, I
assumed that respondents to the HHS surveys, which were used for comparative
purposes, answered the questions honestly. It was also assumed that the established
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statistical methods employed in this study were reliable and representative of the national
population. Additionally, I assumed that the influence of mass media on society
(Bandura, 2001) is substantial and the pharmaceutical industry is aggressive in nature
(Angell,

2011).
Scope and Limitations

I collected data via an online survey posted on two survey websites: a university
participant pool and SurveyMonkey. The survey was adapted from the research
instrument used in 2004 by the FDA. Only college students participated in the present
study. However, the original data were collected from three national surveys (two surveys
involving patients and one survey involving physicians) conducted by telephone. The
original FDA population consisted of individuals in the United States with a listed or
unlisted telephone number. No monetary incentive was offered in the FDA study or in the
present study.
One possible limitation to the present study was the sample size. Due to the
voluntary nature of this study, there was not a large sample. Sampling error can occur
when some persons in the population are omitted (Fowler, 2014). To address this
concern, the minimal sample size was calculated. The inclusion criteria for this study
included adult students who had visited a health care provider within the last year for a
health condition of their own (the same inclusion criteria used in the original FDA study).
The comparative data used in this study were collected in the Patient and
Physician Attitudes and Behaviors Associated with DTC Promotion of Prescription
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Drugs study conducted by the FDA in 2004. Although the OPDP has conducted other
research relating to DTCA, the 2004 study conducted by the FDA was the only survey
type study at the time the present study was conducted. Because the 2004 FDA study was
one of the first studies in the area, only general questions were used on the instrument.
Also, no analysis of the comprehension of the advertisement was included. Additionally,
the FDA survey did not distinguish the type of medium for the DTCA exposure, which
may differ from television, print, Internet, or radio. Although a random sample of
telephone numbers (including both listed and unlisted numbers) were included in the
FDA study, individuals without such service were not represented in the present study.
Additionally, like the previous FDA study, the research instrument used in the present
study was administered only in the English language.
Significance of the Study
The purpose of this study was to determine the association between DTCA and
health care-seeking behaviors in an academic community and to explore patient
perspectives on the issue related to the patients’ overall health care experience. If there is
an association between the advertising component of DTCM and health care-seeking
behavior, then there could be an overuse of unnecessary medication. Additionally,
patients who receive and consume unnecessary medication may experience a subsequent
unnecessary decline to their health status and bear an additional cost burden. The longrange outcome from these findings may indicate a need for stricter FDA guidance and
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regulations, changes in federal and state health care policy, and possible changes to
patient interaction and health care management.
This study will provide a greater understanding and insight into opportunities to
mitigate the potential adverse impacts of DTCA. Overuse, inordinate cost burdens on
patients; health care organizations exploiting loopholes in public policy; patients,
employers, and governments losing limited resources through inappropriate prescription
drug use; and the diversion of innovation and research efforts to profitable drugs at the
expense of drugs that could have a clinical impact are all potential negative outcomes
resulting from inappropriate DTCA (Suh, 2012). Additionally, physicians feeling
pressured to switch patients from known, effective, less expensive and older medications
to new, more profitable medications, as well as the potential increased physician
workload that may prevent more ill patients from obtaining limited appointments are
other negative outcomes that this study can help to prevent. DTCA has a potential that
can be leveraged for good, provided that responsibility is exercised.
As pharmaceutical companies are viewed as one of several contributors to the
sustainability of the health care industry, this study can provide information on focusing
DTCA efforts to help improve the availability, dependability, capability, affordability,
and marketability of prescription drugs. As outlined by Mathaisel and Comm (2014),
these abilities can help the health care industry to minimize waste, create value, and
remain productive for the long term. According to Mathaisel and Comm, the United
States is ranked 37 out of 191 on overall health system performance by the World Health

22
Organization. Further, of the seven industrialized nations, “the U.S. ranked last on
quality, efficiency, access, equity and ability for citizens to lead long, healthy lives”
(Mathaisel & Comm, 2014, p. 1046). In terms of cost-benefit, the United States is viewed
as a poor “value” for health care, given the higher expenditures per capita that fail to
yield the expected benefits or outcomes. Along with patient overtreatment, medical
errors, failures in coordinating care, confusing bureaucracy, and fraud, pharmaceutical
firms are believed to contribute to this less-than-optimal performance. This study will
provide clearer information about pharmaceutical company opportunities that could,
through patients, help to reverse these adverse national trends.
Increase in the use of DTCA by pharmaceutical companies suggests that this
practice is profitable (Sanky, Berger, & Weinberg, 2012; Yaqub, 2014). Given the
potential opportunity for positive or negative impact, Goldberg (2013) called for more
quantitative assessments of DTCA to better understand its impact. This study will help to
address this gap in the literature and offer opportunities for focusing further research in
more appropriate areas. By providing a clearer understanding of the impact of DTCA,
this study will provide managers and executives, as well as governments and legislatures,
with information that can help to guide policy development, strategies, and health plan
decisions. This guidance can help to ensure that patients have adequate information to
make appropriate decisions, may drive education-adjusted DTCA, and can help to reduce
risks for patients. Also, guidance has the potential to reduce costs for governments and
employers, and can increase the awareness of inappropriate off-label advertising. This
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information can also help to redirect limited economic resources to provide a greater
impact on society by supporting a healthier workforce and economy (Huebner, 2014).
The pharmaceutical industry has the potential and ability to positively or negatively drive
hundreds of billions of dollars of direct costs and unknown billions in indirect or soft
costs. A deeper understanding of DTCA is necessary for better managerial, clinical, and
health policy decisions.
Summary
DTCA is a lucrative practice in the pharmaceutical industry. With the overall
financial success of this industry using DTCA and the associated demand for significant
returns by investors, discontinuing such practices is not likely. Regulation by the FDA
attempts to protect the public; however, patient health-seeking behaviors are a concern.
The purpose of this study was to determine the association between DTCA and health
care-seeking behaviors, which were researched through two hypotheses. Additionally,
patient perspectives were explored as they related to the overall health care experience.
This study was quantitative and used an online university participant pool and
SurveyMonkey to collect survey data. The survey instrument administered in the present
study was used in the original FDA (HHS) 2004 study. The independent variables were
patient exposure to advertising, sociodemographic characteristics (i.e., age, gender,
income, and ethnicity), health status, and education. The dependent variable, health careseeking behaviors, were composed of two variables: physician office visits and asking for
a prescription. Only college students were eligible for participation in the present study.
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Honesty by the respondents to the original FDA study and the present study, the
influence of mass media, and the aggressive practices of pharmaceutical companies were
assumptions of this study.
The remainder of the study is organized as follows. Chapter 2 includes a review
of the literature on the subject. Chapter 3 contains an explanation of how the study was
designed. Chapter 4 includes a discussion about the outcomes of the study. Chapter 5
includes a discussion about the conclusions drawn from the study and an explanation of
the recommendations for further research.
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Chapter 2: Literature Review
This review of the literature includes a discussion about the history of the FDA,
which monitors advertising of prescription drugs. Literature that encompasses various
positions regarding the DTCA debate is also included, as well as literature about the
impact of DTCA on pharmaceutical companies and health policy. The theoretical
framework section includes social cognitive theory, choice, and agency theory as related
to advertising. Global consumer culture positioning is addressed in this review. The field
of research on this topic is limited; however, it continues to grow (Goldberg, 2013). Most
studies conducted by the FDA have been experimental in nature. Several researchers
have used data from the original FDA (HHS, 2004) study to further this research base.
However, patient attitudes may have changed over the last 10 years. The present study
adds to the current field of research and serves as a comparison to other study findings.
Title Searches, Journal Articles, and Research Documents
I used refereed journal articles, scholarly books, and research documents through
Internet search engines that included ProQuest Central, ProQuest Health & Medical,
Academic Search Complete, Business Source Complete, Cumulative Index to Nursing &
Allied Health Literature (CINAHL) Plus, Communication & Mass Media Complete,
PsycARTICLES, PsycBOOKS, ProQuest Digital Dissertations, EBSCO ebooks, and
SAGE Premier. Similar research tools from several local university libraries
complemented the online research.
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Background
The idea that certain expensive medications can only be obtained with a
prescription from a physician has stirred controversy. Because there are physician
incentives for the marketing of these medications to consumers (Jofre, 2014;
Kmietowicz, 2014), a better understanding of these interactions is warranted. These
potential conflicts of interest between physician and patient may present significant
concerns (Brill, 2013; Korn & Carlat, 2014; Perry, Cox, & Cox, 2013). To clarify one
aspect of this situation, I sought to identify the relationships between DTCA and patient
medication-seeking behaviors.
Consumer behavior as it relates to DTCA was considered in this study within a
theoretical framework that included social learning theory, information integration
theory, prospect theory, and emerging theoretical constructs from published works. This
framework served as the basis for the hypothesized relationships between DTCA, office
visits, asking for a prescription, and several other variables. I considered the potential
impact of DTCA on patients seeking access to prescription medications that can only be
obtained from a provider licensed to prescribe substances that are regulated by the FDA.
History of the FDA and DTCA
The Pure Food and Drugs Act (1906) marked the beginning of efforts by the
federal government to ensure the safety and veracity of medications. Standards and
quality requirements for pharmaceuticals in Western nations were relatively nonexistent
prior to World War II. The mix of qualified and science-based pharmacists and ill-
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prepared distributors created an increased degree of confusion for consumers. This
confusion was further exacerbated by the limited scientific knowledge of the period and
the tendency of consumers to exercise several different options (Kastner, 2011), making
inferences beyond the anecdotal difficult. The increasing potency and danger of
formulations in the 1930s further transformed the environment by introducing the
concept of so-called “wonder drugs” with increasingly positive outcomes within the
advertisements. However, there were significant negative side effects from these
increasingly potent medications provided support for increased governmental oversight
and regulation (Kastner, 2011).
Furthering the aim of public safety, the Federal Food, Drug, and Cosmetic Act
(1938) gave the FDA oversight of medication production and dispensing to ensure a more
accurate accounting of the risks and benefits of formulations (Kastner, 2011). Since 1951,
federal law has required that drugs be prescribed by a physician if they pose a high risk of
harm if used incorrectly or abused. Through the Kefauver-Harris amendments, the FDA
was given unprecedented and increasing enforcement authority in 1962 to demand drug
efficacy and safety from manufacturers and distributors (Kastner, 2011). Wellington
(2010) described DTCA in terms of a human right in which the patient has access to the
information needed to make health-related decisions. This view of DTCA gives patients
informed control over their health related decisions.
With the ultimate goal of public safety and informed consent, the FDA has
considered the authenticity of claims and made appropriate adjustments to prescribing
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guidance, limits, and restrictions. Achieving this goal, based in clinical research and
outcomes feedback, has become increasingly complex with the evolving nature of
formulations and increasing opportunities for off-label usages that are discovered through
advancements (Sashegyi, Felli, & Noel, 2013; Sawyer, 2012). However, the ratio of
benefits to harm for patients taking newer medications varies with the marketing of the
drug (Brody & Light, 2011).
There are four steps that a pharmaceutical company must take to obtain FDA
approval. The first step is known as the preclinical trail (Hawthorne, 2010). This process
involves testing the drug on animals to determine initial suitability for human testing.
During this stage, the drug company submits summaries of the animal test results and
discusses the manufacturing process. This stage also requires an outline of how the drug
will be tested on humans. The second step (Phase I clinical trials) involves testing the
drug on healthy volunteers to determine safety (Hawthorne, 2010). This trial consists of a
small group of healthy participants. Stages 3 and 4, also called Phase II and Phase III
clinical trials, consist of participants with the disease (Hawthorne, 2010). The trials
during Phases II and III involve a larger participant pool than in Phase I. After
successfully completing Phase III, a company can submit an application to start selling
the drug (Hawthorne, 2010).
The FDA has established standardized guidelines on how long the human trials
should last to assist companies through this challenge. There are also a general number of
groups involved in the phases. Phase I is typically made up of groups of 20 or 50
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participants (Hawthorne, 2010). If Phase I is determined to be safe, Phase II would then
include several hundred people with the disease that the drug is meant to target
(Hawthorne, 2010). Phase II can last for 2 years before Phase III begins. Phase III
consists of several thousand patients, typically over the course of 3 years (Hawthorne,
2010). Another challenge faced by drug companies is FDA bureaucracy involving
selecting the right- or best-fit division for the proposed drug within the FDA.
Like other governmental agencies, the FDA continues to face many challenges.
Political influence is one of many pressures on the FDA. Hawthorne (2010) presented the
Reye’s syndrome occurrence in the 1980s to illustrate the extent of this pressure. Reye’s
syndrome in children occurs after a viral infection and leads to death in 20% of cases; it
is also associated with mental retardation. The Centers for Disease Control and
Prevention (CDC) concluded there was a link between Reye’s syndrome and aspirin.
Although this information was submitted to the FDA, protests from the aspirin industry
resulted in the FDA withdrawing its decision to require warning labels. The warning label
requirement was passed by Congress more than 5 years after the CDC acknowledgments,
after an interest group sued the FDA. Another problem of the FDA is a history of having
approved products that are later found to be dangerous, such as the Bjork-Shiley artificial
heart valve, which resulted in approximately 500 deaths (Hawthorne, 2010).
Drug companies are not required to obtain FDA approval prior to disseminating
an ad. According to FDA regulations, prescription drug ads cannot be misleading or omit
material facts (Avery, Eisenberg, & Simon, 2012). The ads must present a “fair balance”
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regarding the presentation of risks and benefits. Additionally, if an ad is in print, the
format must include information in a “brief summary about side effects,
contraindications, and effectiveness” (Avery, Eisenberg, & Simon, 2012, p. 252). These
guidelines attempt to present the necessary information for patients to make informed
decisions.
Pharmaceutical Industry and DTCA
There can be various reasons why DTCA is used in the industry. Pharmaceutical
companies often use DTCA in an attempt to improve their brand name, as well as to
influence patients to use their particular product. Menon, Deshpande, Perri, and Zinkham
(2003) conducted a study to determine if consumers attend to the brief summary of the
risk information in the print DTCA. This summary is one of the requirements set by the
FDA. The secondary objective was to determine if consumers found this information to
be useful. Data collected from a 1999 national survey on consumer attitudes toward
DTCA were analyzed. A national sample of telephone numbers was purchased by the
magazine, with a sample size of 1,205. Ten combined hypotheses for the two objectives
were developed. For Objective 1, the hypotheses were as follows:
H1:

General consumer characteristics (age, sec, race, and educational level)

influence whether consumers pay attention to the brief summary.
H2:

Consumers’ interaction with DTCA influence whether consumers pay

attention to the summary.
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H3:

Consumers’ attitudes toward the concept of DTCA influences whether

consumers pay attention to the brief summary.
H4:

Consumer characteristics specific to health care influence whether

consumers pay attention to the brief summary. (Menon et al., 2003, p. 183)
For Objective 2, the following hypotheses were developed:
H5:

General consumer characteristics influence usefulness of the brief summary

in discussions with physicians.
H6:

Consumers’ interactions with DTCA influence usefulness of summary

discussions with physicians.
H7:

Consumers’ attitudes toward the concept of DTCA influence usefulness of

brief summary in discussions with physicians.
H8:

Consumers’ attention-related characteristics influence usefulness of brief

summary in discussions with physicians.
H9:

Consumers’ perceptions of the clarity of the brief summary influence its

usefulness in discussions with physicians.
H10: Consumer characteristics specific to health care influence usefulness of
brief summary in discussions with physicians. (Menon et al., 2003, p. 183)
Menon et al. (2003) used a variety of measurement methods to analyze the data,
including using yes/no as the dependent variable and demographic factors as the
independent or predictor variable.
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From the consumers surveyed with no missing responses, 438 subjects remained
with an average age of 42. Additionally, the majority of the participants were women
(62.5%) and Caucasian (87.58%). In summary, the results from the analyses supported
H1, H2, and H3. Under Objective 2, H8 and H9 were also supported. However, the
participants that consumed more prescriptions were significantly less likely to attend to
the summary, which did not support H4. Additionally, under Objective 2, H5, H6, H7,
and H10 were all not supported. Menon et al. (2003) reached the conclusion that, when
attending to the summary of DTCA, the consumer’s age was not relevant and neither was
the number of prescriptions taken. Also, those who read the entire summary were less
likely to find it to be useful (Menon et al., 2003).
For the last 13 years, Prevention has conducted an annual DTC survey. In 2010,
the data were prepared by Princeton Survey Research Associates International and
consisted of a national sample of 1,501 adults. Interviews were conducted via telephone
and the margin of sampling error was reported at +/- 3%. The results indicated that
consumers believe that pharmaceutical advertising is presented fairly and balanced in
magazines and television. This finding is related to the FDA regulated “fair and
balanced” mandate of presenting the risk and benefits equally. The study also reported
that, for 5 consecutive years, 79% of consumers have either seen or heard the risk on TV
ads, 73% had seen or heard the benefits on TV ads, and 48% had seen or heard the
benefits in ads in magazines. These findings also reported 33% of consumers having
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conversations with their doctor after seeing an ad, which has remained stable over the
past 13 years (Prevention, 2010)(“Prevention Magazine Releases,” 2010).
Because the knowledge and understanding required to make safe and appropriate
medication decisions is so advanced, the general public must rely on the expertise of
physicians to determine the appropriateness and authority to obtain and consume some
high-risk medications (Moore, 2014a). This agency relationship moderates the
conditioning, learning, integration of information, and prospect decisions of the average
person (Noor, Yap, Kok-Hong, & Rajah, 2014). Within this theoretical model, it is
suggested that patients, regardless of their sociodemographic profile, will seek to engage
their “agent” in their desire to be considered for or obtain prescription medications.
Newton and Ford (2013) posed the question of whether business and medicine are
ethically incompatible. They described two types of ethics: professional and market.
When the professional acts in the interest of the client, the behavior is known as
professional or fiduciary ethics. In contrast, market ethics involve each side working in
his or her own interest. In the physician-patient relationship, Newton and Ford (2013)
described the professional ethic as being reflected in the Hippocratic Oath, which states
that no harm or wrongdoing will come to the patient (p. 78).
The economic interests of physicians over patients remains a concern today
(Rusthoven, 2014). However, many changes have occurred in medicine that affect this
relationship. Medical facilities have expanded, and this expansion has increased
competition. There are also more investor-owned health care facilities. The early view
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that medicine is a social good has changed to one that considers medicine to be a
commodity, where patients select services that they can afford. These changes in
medicine are a few of the many factors that have caused providers to compete for patients
and make decisions that may be based on profits (Rusthoven, 2014).
Factors Having an Impact on Health Policy
The health policy aspirations of the federal government, the capitalistic goals of
big business, and the incentives for pharmaceutical firms and investors, have suggested
an additional area for consideration (Mackert et al., 2013). Although there is evidence
that DTCA reduces costs by reducing preventable care caused by patient noncompliance
(Bergner, Falk, Heinrich, & Hölzing, 2013), significant potential downsides exist
(Rodwin, 2013). The heightened degree of regulation by the federal government may
have fostered public confidence and reduced perceptions of risk. This reduced perception
of risk may have also created a secondary effect of encouraging questionable utilization.
Essentially, because the medications are deemed safe, more consumers who otherwise
would not seek or even need prescription drugs may desire them. Three of the apparent
downsides of such questionable utilization are opioid abuse (Fischer, Keates, Buhringer,
Reimer, & Rehm, 2014), testosterone over-prescribing (Gan, Pattman, Pearce, &
Quinton, 2013), and the resistance to antibiotics that some organisms have developed due
to antibiotic overprescribing. This increase in questionable utilization may also lead to an
increase in patient complaints (Lewin, 2013) and litigation.
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An additional concern is one of underuse. On the heels of the Great Depression,
fear of a recurrence may have influenced health policy towards ensuring that consumers
did not go without needed medications. An economic theory supporting this argument
was that underuse would lead to higher prices that exclude the less affluent. The
combination of these concerns, intents, agendas, and goals are believed to have framed
the development of advertising, price and patent rules, and guidelines of the period.
Prices, profits, patents, and advertising were increasingly viewed as vital elements of the
effective development and use of modern technology. This statement is not meant to
suggest malicious intent, but is important in understanding the basis and rationale for
legislative activity and decisions by pharmaceutical firms and associated businesses.
However, history does suggest that regulatory legislation benefits have been heavily
weighted towards business and industry, and less so towards consumers (Blair, 2014;
Jofre, 2014; Kmietowicz, 2014).
Some of the world’s largest pharmaceutical companies are located in the United
States and Great Britain. Among the largest in the United States are Pfizer, Merck,
Johnson & Johnson, Bristol-Myers Squibb, and Wyeth. The British companies include
GlaxoSmithKline and AstraZeneca. As prescription drug prices rise, so does the profit
margin for these pharmaceutical companies. Americans spend billions of dollars on
prescription drugs each year. Many pharmaceutical companies argue that high drug costs
are due, in part, to research and development (R&D). However, Angell (2011) argued
that R&D has little to do with these rising costs and pointed out three reasons to support
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her position. First, the total amount spent on R&D makes up a relatively small part of the
drug company budgets (Jack, 2014). Second, the number of completely new drugs
developed is small. Many drugs are only variations to other already existing drugs
(Angell, 2011; Boumil & Curfman, 2013). An example of this practice involves Claritin
(used for allergies) by Schering-Plough, which originally made up approximately onethird of Schering-Plough revenues before expiration of the patent. In an attempt to regain
revenues, the company tried to get users to switch to another patented drug, Clarinex,
which was almost identical to Claritin. The third argument against R&D costs is that
companies can charge whatever they want for the drugs with no or little restrictions from
the government (Peterson, 2014). In fact, the same drugs are often priced higher in the
United States than in other countries. Pricing is driven, in part, by return on investment
demands by shareholders.
Many pharmaceutical companies claim that R&D takes many years and is
extremely costly. The R&D process is divided into two stages: preclinical and clinical.
During the preclinical stage, companies try to find promising drugs to treat a targeted
property. This stage is often computerized and involves testing various molecules to
possible drug candidates. It is the clinical testing phase that is often expensive (Sashegyi
et al., 2013).
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Theoretical Framework
Social Cognitive Theory
Bandura’s (2001) social cognitive theory combines elements of conditioning and
learning with cognitive aspects while extending internal factors to explain behavior.
Thorpe and Olson (1990) explained that Bandura’s theory attempts to clarify behavior by
examining environmental influences. Reciprocal determinism is the term used to explain
the interactional process in the shaping of behavior. The interaction between the
environment, the person, and the behavior have an equal impact on or influence of one
another. Such interactions can include situations in which a person makes selfadjustments or when a person talks to himself or herself.
Reciprocal determinism is important in explaining how a person learns by
observing or modeling. Bandura (1971) argued that the majority of learning is gained
through a persons’ direct experiences or secondhand observations. Thorpe and Olson
(1990) presented three effects of learning:
1. Observational learning effects: Learning that results from combining
previously learned response in new ways;
2. Inhibitory and disinhibitory effects: The consequences of the model’s
behavior has an impact on the observer’s behavior. An inhibitory effect
discourages the observer from engaging in the model’s behavior. Conversely,
a disinhibitory effect would encourage learning to model the observed
behavior.
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3. Response facilitation effects: Generally, a person performs acceptable
behaviors after observing others. The consequences observed influence the
observer’s decision to perform the observed behavior. This modeling process
begins with a person showing attention to the model, which is then followed
by some form of retention of the information. Next, the observer attempts to
put the observed performance together, which sometimes requires small steps.
The forth step involves modeling the behavior, if the motivational factors are
acceptable. (Thorpe & Olsen, 1990, p. 72)
When a person uses previously learned responses in new situations, he or she is
demonstrating observational learning. In inhibitory and disinhibitory effects, a person can
repeat or not repeat an observed behavior of a model based upon the consequences
observed. If the observer is discouraged to engage in the behavior, the person is
exhibiting an inhibitory effect. But, in demonstrating the disinhibitory effect, the observer
is encouraged by the observed behavior. Response facilitation effects can be described as
observing a behavior that is defined as acceptable and following four steps in the
modeling process. First, the observer observes the model and then retains the
information. The observer then compiles all of the observed information together and
then, in the final step, the actual modeling of the behavior occurs (Thorpe & Olsen,
1990).
Modeling can take on many forms, in addition to an actual live model or
observation. Modeling can also take place from observing media, television, and so on.
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This type of model is known as symbolic modeling. Also, covert modeling can take
place, in which the observer imagines observing a model. According to Bandura (1969)
imitating an observed behavior does not have to immediately occur following the
observation.
Bandura’s (1965) experiment on imitation of aggressive behaviors was an attempt
to explain learning by observation. Bandura used four-year-olds in this experiment on
imitation of aggressive behavior. The experiment involved each participant individually
observing an adult perform four aggressive behaviors against a Bobo doll on film. The
behaviors included both physical and verbal aggression. The adult sat on the doll and
punched it, hit the doll with a mallet, kicked the doll, or threw rubber balls at the doll (all
physical behaviors were coupled with verbal aggressive statements). The child
participants then observed the adult being reinforced with snacks and verbally praised;
punished and scolded; or having no consequence implemented. The children were then
taken into a room with a Bobo doll and other toys. The findings showed aggressive
behavior by the children, often with similar actions that resembled those of the model.
Social Cognitive Theory and Choice Theory
The role of reinforcement and other elements of social cognitive theory in the
learning process were compared and debated by Malone (2002) in a compatibility
analysis with Glasser’s (2010) choice theory. Although both theories support individual
responsibility, the two theories differ in regard to views on reinforcement, punishment,
and self-efficacy. Choice theory states that all behavior is chosen and the most important
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need that a person possesses is love and belongingness (Glasser, 2010). Behavior is
described as humanistic, and a person’s behavior is determined by survival, love and
belonging, power, freedom, and fun (Malone, 2002). The term reinforcement, which is
used in social cognitive theory, was not used by Glasser due to the external nature that is
implied by the term. Glasser’s choice theory stresses internal control and views
punishment as an unethical and ineffective practice. Additionally, punishments and the
administration of rewards are seen as manipulating and coercive techniques. Internal
motivators can be eliminated if behavior is manipulated. Bandura’s (1965) research with
Bobo dolls illustrated the use of learning by watching others and vicarious punishment.
One of several similarities between social learning theory and choice theory is the
decision to perform a learned behavior. A person can learn a behavior in both theories but
many decide when or if to perform. Malone (2002) stated that, according to choice
theory, a person creates images in his or her mind. These images form a persons’
personal quality world. A person can retain these images or go to the next step of actually
acting out the activity. A persons’ actions can be changed in both social cognitive theory
and choice theory. However, in cognitive theory, changing behaviors is accomplished
though a person changing the pictures within his or her quality world and not the actual
alteration of a behavior, as is the case according to social cognitive theory. Human
behavior is regulated by self-efficacy, and the concept is an important aspect of both
theories. Cognitive, motivational, affective, and selection aspects are all involved in the
self-efficacy process.
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Social System
Bandura (2002) discussed how social cognitive theory adapts to human
development, adaptation, and change as part of the social cognitive theory in cultural
context. Culture is described as a social system that is diverse and changing; therefore,
human functioning within culture is unique. According to Bandura, there are three modes
of agency (an intentional influence on a persons’ functioning, which includes a persons’
life circumstances): direct personal agency, proxy agency, and collective agency.
Whereas personal agency involves a persons’ own direct control over conditions, proxy
agency relies on others to have a secure wellbeing. Collective agency relates to group
actions in accomplishing desired outcomes. Bandura stated that people have limited
direct influence or control over social conditions or institutional practices, and people
must combine their skills and resources to accomplish many individual goals.
Cultural differences have an impact on how these three modes of agency mix for
successful functioning. All three types of agency are needed each day, regardless of the
specific culture. Despite the agentic blend, personal efficacy plays a critical role in a
persons’ actions. Personal efficacy is a persons’ beliefs regarding his or her power to
produce the desired outcome. Human functioning, which includes cognitive,
motivational, affective, and decisional processes, are all regulated through a persons’
personal efficacy beliefs (Bandura, 2002).
The role of culture was debated by Bandura (2002) in terms of whether a
universal human nature exists or if there are several human natures that combine in
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various cultural situations. Both direct and vicarious experiences shape human nature.
However, biological limits exist that influence the shaping of human nature. These
biological limits were described by Bandura as permitting a broad range of possibilities
within a persons’ culture. People adapt to their environments by using various agentic
modes, while adjusting as needed to overcome physical limitations or restrictions.
Cultural differences exist both cross-culturally and intraculturally; however,
“globalization and pluralization of societies” has ended the insular nature of cultures
(Bandura, 2002, p. 283) Culture is displayed in a persons’ style of living. Culture has an
impact on a person’s choices. Material and nonmaterial are the two parts of culture.
Culture can be described as habits that encompass diverse factors to include morals and
laws (Kahle & Chiagouris, 2014). Additionally, Kolesnik (2013) using Hofestede,
Hofstede, and Minkov’s (2010) cultural dimensions theory asserted that people from
different places are distinguished by culture.
Advertising and Social Cognitive Theory
The influence of mass media on society is substantial, requiring an explanation of
the psychosocial role of communication and human behavior. Bandura (2001) described
psychosocial functioning using a triadic reciprocal causation model that consists of
personal, behavioral, and environmental determinants. In general, people are proactive
and self-reflecting beings. Human nature is shaped or molded by direct and observational
experiences within biological limits. Behavior is impacted cognitively by external
influences rather than directly, and cognitive factors also determine which environmental
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situations will be observed. A persons’ own knowledge and understanding is derived
from operating symbolically on personal and vicarious experiences (Bandura, 2001).
Bandura (2001) also described people as self-reactors. Through internal standards
and reactions to a persons’ own behavior, one can self-regulate motivation, affect, and
action. This self-regulation is not limited to negative feedback of oneself, but also on
motivation. This motivation was described by Bandura as a person setting challenging
goals and mobilizing resources to accomplish these goals. People have internal standards
that assess the adequacy of established achievements. Internal standards also regulate
conduct, both socially and morally. Internal standards can slowly change, but are usually
stable. Morality (right or wrong) was described by Bandura as inhibitive and proactive.
Inhibitive morality is a persons’ power to refrain from inhuman behavior, and proactive
morality is the power to behave humanely.
Bandura’s (2001) social cognitive theory also described people as being selfreflective. This process involves a person generating ideas, acting upon them, and then
judging adequacy. Fours modes (enactive, vicarious, social, and logical) exist in the
verification of a person’s ideas or thoughts. The fit between a persons’ thoughts and
action results in what occurs with enactive verification. This type of verification
corroborates thoughts (a good match) or refutes them (a mismatch). When a person
observes another’s actions, he or she can check the correctness of his or her own thinking
process, which is vicarious verification. Social verification is conducted when one checks
a persons’ views against the beliefs of others. Logical verification involves checking
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fallacies by deducing from known knowledge. Each of these four verification forms can
produce faulty thinking. Bandura (2001) presented examples of this faulty thinking in an
illustration in which distorted media versions of reality fostering shared misconceptions.
In 21st-century society, consumers are presented with images through media that
would not otherwise be available in their lives. Bandura (2001) summarized four
subfunctions that govern observational learning, such as through media. The subfunctions
are attentional processes, cognitive representational processes, behavioral production
processes, and motivational processes. Attentional processes are those in which a person
selectively observes modeling. Factors that determine selection include cognitive skills,
preconceptions, and held values. Bandura described cognitive representational processes
in terms of memory retention. Observed events must be remembered to be influential;
therefore, a process must occur that will change or transform the modeled event into a
useable form. The third process, behavioral production, is the transformation of a concept
into action. The final process involves motivational aspects that determine what
encourages a person to perform the acquired behavior, because not all observed behavior
is performed.
Conflicts sometimes occur when there is a conflict between observed events and
internal moral standards. Additionally, vicarious motivators, such as punishment or
reward, can influence the performance of the observed behavior by an observer.
According to Bandura (2001), television and other forms of media often glamorize
representations that may cause internal discord. This portrayal may work as a
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motivational element to influence a person’s behavior. Bandura argued that the media can
both create and alter personal attributes. Technological advances have contributed to
communicating to large numbers of people in a single transmission.
DTCA persuades people to use medications that they may not need, creating more
harm than benefits (Rollins & Perri, 2014). There is also evidence to suggest that DTCA
has the potential to influence patients’ perceptions of treatment plans (Byrne,
Niederdeppe, Avery, & Cantor, 2013). Physicians are also not immune to the social
psychologically based efforts of pharmaceutical firms (Ball & Mackert, 2013; Sah &
Fugh-Berman, 2013; Sismondo, 2013). New drugs are profitable and, although some
testing has been done, long-term effects are not known. DTCA influences patients to take
these new drugs with sometimes unknown risks. The advertised drug is often new and
inferior to older methods, but is more expensive. Established medications are often not
advertised as heavily because of generic competition (Ross & Kesselheim, 2013; Tenn &
Wendling, 2014).
Pocock (2003) posited for and against non-inferiority trials, the aim of which is
the development of new treatments that are safe. A non-inferiority trial refers to a
“randomized clinical trial in which a new test treatment is compared with a standard
active treatment rather than a placebo or untreated control group” (p. 483). During
clinical trials, no patient is supposed to be denied effective treatment. In some trials, there
may be an active control group and a placebo. Care during clinical trials is important to
prevent the use of ineffective and unsafe treatments. Also, Type I and Type II errors are
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to be avoided. As Pocock (2003) explained, “a Type I error would be the acceptance of a
useless treatment into widespread use,” and “a Type II error is the failure to use an
effective active control treatment by adopting a placebo control group instead” (p. 484).
Most trials involve the patients receiving the active drug. In some trials, the research
participant may already know that the new treatment is different from the active
treatment.
Even with technological advances, diffusion of information differs among
individuals and social groups. Bandura (2001) discussed three processes (innovative
behaviors, adaptation of behaviors in practice, and social networks) that govern social
diffusion of new behavior patterns. According to Bandura, the acceptance of new ideas or
practices is a challenge due to factors such as customs and social unfamiliarity.
Acceptance then takes on an accelerated course followed by a slowdown in the rate of
diffusion. The dispersion of innovative behaviors, which is one of the three processes,
relies on the method of diffusion (e.g., newspaper or television). More complicated
innovations are more difficult for others to accept. In general, for modeling of a behavior
to occur, many factors are involved, including human competency and self-belief
(Bandura, 2001).
Another process presented by Bandura (2001) is adoption, which relates to the
many factors that determine if a person will act or engage in a learned behavior. A person
is more likely to adopt an innovation if there are benefits. These benefits may include
social recognition or status as motivators. People also adopt behaviors that fit into their
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value system. The third process that has an impact on diffusion is the social network.
Whether it is an occupational colleague group, friendships, or kinships, people are often
associated with networks. These networks contain various structural levels and
interconnectedness; however, no one social network can serve all purposes. A person
with many network ties is more likely to accept innovations and have a greater likelihood
of exposure to modeling. Television and online transactions include a few media sources
that cross barriers (e.g., geographic and time) in the transmission of innovations. The role
of mass communication plays an important role in learning.
Social Cognitive Theory and Direct-to-Consumer Advertising
Rosenbaum (1999) used Sen’s (1977) work as an origin and comparison for
research. Sen’s contribution related to culture and consumption. Rosenbaum divided his
work into six sections. The first section of Rosenbaum’s essay explored various views on
consumption. Although Rosenbaum defined and summarized consumer theory, beginning
as early as 1966, a general introduction to Sen’s background and contributions were
limited for a beginner reader. The second section of the article explored the importance
and impact of goods on culture. Rosenbaum (1999) remarked, “In fact, goods receive
meaning as a consequence of being used as markers and they are used as markers because
they carry meaning” (p. 322).
Rosenbaum (1999) suggested that a persons’ identity is established by
commodities. The roles of preferences, cultural capital, and inequality are followed in the
fourth section. Rosenbaum noted that goods carry meaning and should be taken seriously,
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unlike Sen’s (1977) suggestion. Rosenbaum’s essay concluded by examining empirical
evidence related to cultural capital. Here, the author focused on social mobility. Erikson
and Goldthorpe (1992) debated the determinants of social mobility. Rosenbaum focused
on how three claims perform in empirical tests, concluding that the evidence presented by
Erikson and Goldthorpe left some doubt due to the difficulty in representing cultural
capital empirically in research. Rosenbaum concluded that cultural capital has changed
over time. He gave the example of the 20th-century pension system that focuses on the
nuclear family rather than the traditional extended family. In conclusion, considering
culture is an important element. Individuals choose goods based on symbolic meanings
derived from their culture (Rosenbaum, 1999).
The extent of the influence of popular culture may vary. Cusic (2001) attempted
to measure the economic impact of popular culture by gathering data from the U.S.
Department of Commerce. The method by which popular culture is transmitted is the
media; therefore, advertising expenditures were reviewed. Cusic began with a
comparison of advertisement figures for 50 years, starting in 1948, which was the first
full year of television programming. The figures were obtained from the Television
Bureau of Advertising. In 1948, the most popular advertising medium was newspapers,
which received $1.745 billion in advertising revenue, compared to $562 million spent on
radio advertising. In 1948, the total amount spent on advertising was $2.784 billion, of
which television received 0%, radio 20%, magazines 17%, and newspapers 62.7%. In
comparison, in 1994, the advertising expenditures totaled $88.2 billion, of which 40%
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was spent on television advertising, 39% on newspapers, 12% on radio, and 9% on
magazines. Therefore, over the 50-year period ending in 1994, advertising expenditures
continued to increase, with the most popular medium changing from newspapers to
television (Cusic, 2001, p. 1). With the popularity of the internet a shift in the popular
medium may have changed again.
Cusic (2001) discussed several possible reasons for the changes in advertising
channels. One theory suggests that newspaper and television advertising are at-home
activities, whereas radio penetration is primarily outside of the home. These so-called inhome activities have a greater chance of being used. The penetration of radio advertising
may therefore be limited by the reduced amount of time in which listeners engage in this
type of activity. A second assumption to explain medium changes explored the number of
radio stations compared to the number of daily newspapers in a market. In a given
market, there is often one newspaper, but several radio stations. It is more economical to
advertise in one medium than on several radio stations. Cusic reported that the number of
U.S. households with cable television increased to 62.4% in 1995, up from 6.7% in 1970.
The application of these economic findings has an impact on the production of movies,
music, products, and prescription medications (Cusic, 2001). The practices of marketing
prescription drugs directly to consumers began in the 1980s, when the FDA removed
restrictions. The possible effects of such practices on the patient/physician relationship,
prescription writing, and consumer education are all factors that may experience the
impact of DTCA.
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There have been other studies that have used social cognitive related theories and
DTCA. Welch Cline and Young (2004) conducted a content analysis based on Bandura’s
(2001) social cognitive theory. The purpose of the study was to identify features of
DTCA that may function as modeling. Visual cues were examined as vicarious
motivators. Social cognitive theory describes behavior change in terms of rewards
associate with observed behaviors that, in turn, becomes motivators. Motivators may be
direct or vicarious. In DTCA, financial incentives or claims regarding the potential of a
product to cure an illness may be direct motivators, whereas images of healthy, happy, or
socially engaged product users may be vicarious motivators (Welch Cline & Young,
2004, p. 136). The present study used Bandura’s social cognitive theory as part of the
theoretical framework.
Many industries, including alcohol and tobacco, engage in social modeling
through the use of billboard advertisements. Social rewards associated with product
consumption in advertisements are known as relational motivators, whereas the use of
attractive cues are identity motivators. For observational learning to be effective, the
reader must be attentive to the advertisement and associate a positive image.
Additionally, the ad must exhibit the same realities of the reader.
Magazine advertising continues to be a popular medium used by pharmaceutical
companies for DTCA. The study conducted by Welch Cline and Young (2004) consisted
of reviewing advertisements in 18 popular magazines for a two-year period (January
1998 to December 1999). The researchers coded the articles based on factors such as
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whether models were present and the number of people in the ad. Illustrations featuring
rewards were also identified and coded, such as if they were healthy, active, and friendly
models. The first of the four research questions was, What percentage of direct-toconsumer print advertisements depicted models? The results indicate that over 80% of the
advertisements contained models and 35.7% included inanimate objects. Welch Cline and
Young further analyzed the advertisements with models by medical condition.
Advertisements for musculoskeletal conditions and respiratory conditions used people in
the advertisements 100% of the time. Advertisements for allergies, urologic condition,
and dermatologic condition depicted people, 94.3%, 92.3%, and 91.7%, respectively.
Infectious conditions (other than the human immunodeficiency virus [HIV]) and tobaccoaddiction advertisements were the least likely to depict people, both 62.5%, from the
sampled advertisements.
The second research question Welch Cline and Young (2004) asked was, What
are the demographic characteristics of models depicted in direct-to-consumer print
advertisements? The findings showed that either male or female models were commonly
found in advertisements 33.3% of the time. The use of female-only models (38.3%) in
advertisements was more popular than advertisements containing only male models
(26.8%). The authors also found trends in the advertisements based upon the type of
medical condition. Advertisements for cancer disproportionately showed females (75%).
Other types of medical conditions that depicted women more often than men included
obstetric-gynecologic (89.5%), psychiatric-neurological (71.4%), and tobacco addiction
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(60%). The use of men only by medical condition was popular for such conditions as
cardiovascular (66.7%) and gastrointestinal-nutritional advertisements (66.7%).
Advertisements for the drug Viagra (which, for advertising purposes, the type of medical
condition is presented as undisclosed), depicted both a male and a female model in 100%
of the reviewed advertisements.
With regards to ethnic groups, Welch Cline and Young (2004) found nearly three
fourths of the advertisements (71.6%) depicted Whites only. Advertisements with only
African Americans, Hispanics, or Asians were few (14.2%, 1.1%, and .5%, respectively).
Additionally, differences were also found for the type of medical condition and ethnicity.
The depiction of Whites was dominant in advertisements for cancer, cardiovascular,
psychiatric-neurological, respiratory, and tobacco-addiction conditions. African
Americans were most commonly reflected in advertisements for HIV/AIDS and diabetes,
48.4% and 33.3%, respectively. Hispanics were also more likely to be depicted in
advertisements for HIV/AIDS, even though this group was less likely to appear in any
type of advertisement.
Restating RQ3 and RQ4 of the Welch Cline and Young (2004) study (What are
the nature and frequency of identity rewards offered in direct-to-consumer print
advertisements via visual cues, and what is the nature and frequency of relational rewards
offered in direct-to-consumer print advertisements via visual cues, respectively). The
findings of Welch Cline and Young’s (2004) study indicated that in 91.8% of the
advertisements, people that appeared healthy were depicted. Additionally, the majority of
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the advertisements showed people in some form of activity, social activity (17%), and
physical activity (43.4%). Most advertisements also showed either smiling (72%) or
friendly (64.1%) behaviors. The depiction of social contexts was found in many of the
advertisements (40.7%). This social context was often family- or romantically orientated,
31.1% and 29.8%, respectively.
Based on these findings, Welch Cline and Young (2004) concluded that change in
health care behavior might be triggered by DTCA. Consumers are often exposed to visual
models with positive features, such as active and friendly models. Additionally, over 90%
of the advertisements showed only healthy-looking people. Exposure to DTCA may be
misleading and promote stereotypes. Age (Abernathy, Adams-Price, & Henley, 2013),
ethnicity (Ceccoli & Klotz, 2013), where consumers live (Spake, Joseph, & Megehee,
2014), and the mode of DTCA delivery (Bhutada, Deshpande, Menon, & Perri, 2013;
Huh & Shin, 2014; Koch et al., 2014; Vats, 2013) have also been found to have potential
impacts on consumers’ perceptions. The present study may add to the debate regarding
ethical questions surrounding the use of DTCA. This study presents a comprehensive
discussion regarding the power of DTCA and states that analysis supports observational
learning, which can influence to relationship between physician and patient.
Given these theoretical perspectives, patients are believed to synthesize
information that encourages them to seek medications that reduce the disparity between
their current perceived health status and wellness, and their desired health status and
wellness. DTCA could provide consumers with information to develop the perception or
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belief that the advertised medication could provide better options and more favorable
health status alternatives. This consumer information processing typology suggests that
DTCA can make an impact on consumer behavior by developing the cognitive processes
that synthesize information, develop a need for a change in health status or standing,
identify a solution to that need, and encourage a desire to act on that need by seeking
medications (Mukherjee et al., 2013).
Moderating and Other Theoretical Constructs
Most consumers do not possess the educational background, pharmaceutical
knowledge, or experience to appropriately understand medication risks. Additionally,
they do not have the authority or ability to obtain prescription drugs without physician
approval. As a result, social learning, information integration, and prospect theoretical
postulates must be mediated or at least moderated within the context of agency theory
(Epstein & Ketcham, 2014).
Agency theory suggests that situations involving information asymmetry or lack
of decision-making authority require a qualified “agent” to act on behalf of the consumer
(Epstein & Ketcham, 2014; Wang, Dou, Li, & Zhou, 2013). Principle-agent relationships
are found in many industries and products, from real estate to accounting to prescription
drugs. Associations involving these principle-agent relationships must involve sound
ethical and moral standards, given the redistribution of value that creates the relationship
(Epstein & Ketcham, 2014). In the case of the present study, the consumer-physician
relationship required for a prescription is at least partially facilitated by DTCA. This
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facilitation, coupled with consumers’ limited knowledge of behavior-shaping learning,
information processing, and risk factors, completes the theoretical framework required to
better understand the impact of DTCA on prescription-seeking behaviors (Arney &
Lewin, 2013; Spence, 2013).
In keeping with the tenets with agency theory, consumer search behavior, at least
in part, is motivated by perceived risk and consumer ability to acquire pertinent
information to determine whether a purchase is necessary. In the case of prescription
drugs, this risk can be defined as a diminished health status, illness, injury, or even death
(Fountain & Reith, 2014; Ross & Kravitz, 2013). Anvari and Amin (2010) provided
further support for the mediating effects of perceived risk and the increased consumer
search activity. This phenomenon is known as surrogate consumption theory. The theory
focuses on those who must or believe that they must rely on other persons for the
acquisition- and consumption-related activities that they desire (Lantos, 2010). Given
disenfranchisement, a lack of opportunity, or an inability to act on their own behalf,
consumers often engage in surrogate consumption activities. Galbraith’s controversial
thesis suggested that large corporations seek to manage the demand for their products
(Goldberg, 2013). Implying that the direct manipulation of consumers’ fuels product
demand, this thesis provides a potential financial explanation for why DTCA may
increase demand (Goldberg, 2013).
The FDA OPDP investigates the applied/theoretical issues relating to the
communication of risk and benefit for DTCA and professional promotional prescription
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drug material (HHS, 2013). In 2011, several experimental research studies were
completed by the OPDP. In its 2012 study, the FDA investigated alternative formats for
presenting the brief summary statement and examined how people read through and
understand the summary. The study findings showed that adding a serious risk to the
statement being read did not increase or decrease the overall amount of time taken by the
participants. The readers’ intention of asking for the prescription also did not change
under these circumstances. Additionally, individual characteristics had a greater influence
over reading time compared to characteristics found in the ad statement.
The FDA (2012) found that the amount of time spent reading the display page and
summary were significantly related to the reading speed, age, and health of the reader.
Finally, there was evidence to support that serious risk information scares possible
consumers away. Focus groups are also used by the OPDP to gather information as
related to DTC advertising. The Food and Drug Administration Amendments Act
(FDAAA) of 2007 has assisted in providing resources for ongoing research and reviews.
Alden et al. (1999) offered global consumer culture positioning (GCCP) as an
alternative approach to brand positioning design for international positioning. The
researchers examined and contrasted GCCP with local consumer culture positioning
(LCCP) and foreign consumer positioning (FCCP). GCCP involves sharing symbols that
denote membership in a global consumer segment. These shared symbols can take on
several forms, such as language. Alden et al. used the example advertising with the
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English language, which is viewed as modernism. English is therefore used for a brand to
convey this associated meaning.
Alden et al. (1999) formulated eight hypotheses. First, all three positioning
approaches are meaningful in television advertising. Second, the most commonly used
strategy in television advertising is LCCP. Third, in the United States, GCCP is used less
frequently in television advertisements. Fourth, in the United States, LCCP is used more
frequently in television advertisements. Fifth, in television advertisements, more indirect,
image-oriented approaches are used when GCCP is employed. Sixth, if GCCP is used,
food products are less often represented, whereas durable goods often use this approach.
Seventh, in television advertising for food, LCCP is used most, but LCCP is used least
often for durable goods. Eighth, for services, LCCP is more often used.
A broad array of Asian and Western cultures (e.g., United States, Germany,
Korea, India, Thailand, France, and the Netherlands) were selected by Alden et al. (1999)
to participate. Alden et al. selected random samples of television advertisements from
each country. A random sample of 20% to 25% of ads was then taken from all collected
advertisements. A total unduplicated sample of 1,267 remained. Graduate students
conducted in-depth coding for each of their native countries.
The results supported Alden et al.’s (1999) primary hypothesis, with 85% of
advertisements displaying one of the three positioning options, GCCP, LCCP, or FCCP.
The researchers’ second hypothesis was also supported, with 59% of advertisements
using LCCP, compared to 22.4% that used GCCP and less than 4% that used FCCP.
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Additionally, Chi-square analysis resulted in support for Alden et al.’s third and fourth
hypotheses, both of which relating to positioning in the United States. Significance was
found for types of products that used GCCP, with 56.3% of advertisements using soft-sell
approaches, which supported Alden et al.’s fifth hypothesis. The other findings also
support the sixth, seventh, and eighth hypotheses. GCCP was found to be highest (33.3%)
for high-tech durables, but was only 18.6% of food advertising. In service advertising,
LCCP was most frequently used often positioning option.
Alden et al. (1999) concluded that the then relatively new approach of GCCP may
be beneficial. For example in economically developing countries, GCCP may work more
effectively than might LCCP. This study contributed to the existing body of knowledge
by adding an alternative approach to advertising. The researchers acknowledged several
limitations in their study, including coding and interpretation of advertisements. The
study appeared to be generalizable, with the use of seven diverse countries (Alden et al.,
1999).
Voluntary simplicity (VS), which has evolved in meaning over the years, can be
defined as a commitment to the nonmaterial aspects of life or living a simpler life. In
practice, a person minimizes consumption of material goods and may even carry over to
working less (Ekstrom & Glans, 2012).
Shaw and Newholm (2002) examined the differences between ethical
consumption behaviors and voluntary simplified behaviors, and presented findings from
two qualitative studies that explored consumer behaviors. Briefly defined, VS is a
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consumer’s choice to simplify individual consumption behavior. In comparison, ethical
consumers restrain from consumption because of some ethical concern, such as taking
public transportation rather than driving a fuel-inefficient car. Shaw and Newholm (2002)
stated that “a fine distinction cannot be made between the extent and nature of
consumption in affluent consumer societies” (p. 169). Therefore, consumers engage in
the following behavior approaches: downshifting, voluntary simplicity, and sustainable
levels of consumption. Shaw and Newholm described downshifting as a type of VS;
however, downshifters seek to maximum quality time over other motivations, such as
income.
Shaw and Newholm’s (2002) premise was that VS may be demonstrated among
consumers whose behavior includes some ethical consideration of the environmental and
social impact of their consumption choices (p. 180). The two qualitative studies examined
by Shaw and Newholm were conducted in the United Kingdom between 1996 and 1999.
One study consisted of 15 ethical consumers forming two focus groups. The other study
involved 16 case studies of ethical consumers. The respondents’ attitudes in relationship
to three consumption areas (diet, car or non-car travel, and use of secondhand products)
were discussed. Shaw and Newholm reported that, in both studies, the majority of
respondents had modified their diets for various ethical reasons, including treatment of
animals and environmental concerns. Dietary changes included becoming a vegetarian,
reducing meat purchases, only buying free-range animal products, or increasing
purchases of organic products.
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Environmental concerns were one of the issues associated with choices made
relative to transportation. Although some respondents owned cars, they indicated a lack
of or problems with public transportation. Shaw and Newholm (2002) cited that some
respondents decided to live in areas in which employment and amenities were in walking
distance to address the transportation concern. The use of secondhand items was another
choice made by respondents. One respondent reported that it was more economical and
efficient to purchase used products or items, including homes, clothes, and appliances.
The authors concluded that the findings “suggest[ed] that consumers who start from the
premise that ethical issues are applicable to their consumption also consider the extent of
that consumption” (Shaw & Newholm, 2002, p. 180).
Finally, Ahn et al. (2014) and Park, Ju, and Kim (2014) provided empirical
evidence of the positive association between DTCA and consumer perceptions of the
prevalence and risks of depression. By playing a role in creating social reality of diseases
and medicine, the social cognitive effects of DTCA are considered far-reaching and
influencing to pharmaceutical firm marketing strategy. This effect further raises complex
ethical concerns. Although the study was limited to print advertisements for
antidepressants, it provided support for the broader exploration of this phenomenon in
general DTCA. The present study sought to contribute to the overall body of knowledge
regarding DTCA by providing empirical support for the association between DTCA and
consumer behaviors.
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Review of Research Methods and Differing Methodologies
The approach to research designs can be qualitative, quantitative, or a
combination of both. There are many approaches to each design; some of the more
frequently used include field research, experimental, evaluation, and survey. Singleton,
Singleton, and Straits (2010) defined field research as directly observing others in a
natural setting. This form of observation may extend over a period of time and may
include interaction. Case studies are one of two approaches of field research. The other
type of study is known as ethnographies. According to Singleton et al., most field
research involves a case study in that a single unit analysis is examined. In comparison,
ethnographies usually describe a culture based upon long field investigation. Singleton et
al. stated that researchers select this type of research to obtain an insider’s viewpoint. In
addition to observing the unit of analysis or social phenomenon, the researcher can better
understand substance of views within a setting.
Like other research approaches, there are advantages and disadvantages to
using field research. Field research can be less costly in comparison to other methods
because it can be conducted nearby; however, this type of research tends to be laborintensive. Other disadvantages to using field research include replication difficulty and
issues involving generalizability. In situations where the researcher has limited
knowledge about the subject or ethical challenges restrict other research approaches, field
research may be used (Singleton et al., 2010).
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Experimental research is another approach that is described as an empirical
investigation that attempts to describe a causal explanation. In a true experimental
research design, the participants are assigned randomly to either an experimental group or
a control group (Marczyk, Dematteo, & Festinger, 2010). Additionally, according to
Singleton et al. (2010), this type of research entails the manipulation of an independent
variable while controlling exposure or contact to other events. Control of extraneous
variables is crucial due to the threat to internal validity.
Singleton et al. (2010) also defined evaluation research as a type of social science
research that focuses on analyzing social programs and policies. These social programs
are primarily instituted by government entities (federal, state, or local). Evaluation
research uses the same types of methods and addresses many of the same issues as other
research methods; therefore, the designs and validity (internal and external) issues are
similar to those discussed under other methods. The primary distinction is that evaluation
research applies research to social context. Monette, Sullivan, and DeJong (2013)
described three reasons for conducting evaluation research: to test hypotheses, to support
evidence-based practice, and for administrative purposes.
This present study used survey research. Like the other approaches, there are
many advantages and disadvantages to this approach. Marczyk et al. (2010) described
survey studies as a method in which the researcher asks a large number of people
questions. These questions can address attitudes, opinions, or specific behaviors. The
findings from surveys may be limited to describing people’s responses, but an attempt
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may be made to find a relationship between reported behaviors/opinions and the
respondents’ characteristics. Similarly Singleton et al. (2010) explained that the
researcher examines the relationships among the measures once information is gathered
from the survey. Additionally, survey research designs are divided into two categories:
cross-sectional and longitudinal.
The cross-sectional design is one in which data are collected at one point in time
from a sample of respondents selected to represent the target population. According to
Singleton et al. (2010), this one point in time means that the data are collected in the
shortest feasible amount of time. The cross-sectional design has two variations:
contextual design and social network design. Both types of designs can be used to study
individuals within the same social context; however, contextual designs involve sample
cases within a particular group to describe characteristics. In comparison, social network
designs, which often require the researcher to interview every person in the study, are
used to examine the relationship among people or other target performers. Longitudinal
designs are studies in which data are collected at more than one point in time.
Researchers using this type of design may ask the same questions to every individual or
independently select samples from the same population. When repeated surveys are
administered to independent samples of the same population, this type of longitudinal
design is known as a trend study. The other type of study in which the same individuals
are surveyed more than once is known as a panel study. The cross-sectional design is the
more popular of the two designs (Singleton et al., 2010).
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Using the survey approach, researchers often strive to make inferences about a
whole (known as the population) from observations taken from a sample of the whole
(Singleton et al., 2010). Because it is often impossible to observe all actions or events,
sampling may be a solution; a sample that is representative (characteristics are close to
those of the target group) of the target population is used. Typically, sampling reduces
time and cost of a study. Once a researcher has selected the unit of analysis, the number
of units and the method upon which the units will be selected must be decided. According
to Singleton et al. (2010), the first step in sampling is defining the population of interest,
which is a two-step process. The target population, which is the population to which
results are to be generalized, must be identified. This process can be performed by the
researcher by establishing criteria to determine which cases to include and exclude in the
population. Geographic boundary and time frame are two characteristics identified by
Singleton et al. that can assist in defining the researcher’s target population.
The second step is making the target population operational, which requires
constructing a sampling frame. A sampling frame for a survey approach often entails
obtaining a listing of the population or subgroups of the population. Next, a sampling
design is developed. This design establishes how cases will be selected for observation
and falls into two categories: probability sampling and nonprobability sampling.
In probability sampling, all cases have a chance of being randomly selected from
a population. In contrast, nonprobability sampling does not have this known probability
because random selection does not occur. Singleton et al. (2010) discussed five different
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types of probability sampling: random selection, simple random sampling, stratified
random sampling, cluster sampling, and systematic sampling. In random selection, each
case within a population has an equal chance for selection. According to Singleton et al.
(2010), mechanical or electronic aids should be used in this process. Similarly, in simple
random sampling, each case has an equal chance of selection, but this procedure refers to
combinations of cases. In the third type of probability sampling, stratified random
sampling, a subdivision is made to the population first and then simple random samples
are selected from each segment. These subdivisions are mutually exclusive and this
procedure can increase sample precision.
The fourth type of sampling, cluster, also involves dividing the population;
however this breakdown into clusters is according to natural areas or groupings. Random
sampling then occurs from the clusters. Singleton et al. (2010) offered several examples
of clusters to include colleges, churches, states, and cities. Clustering is performed most
often to reduce the expenses associated with data collection. Another type of probability
sampling is systematic sampling in which a researcher chooses a number, then selects a
case with that number from a complete list of the population, such as every 10th case
(Singleton et al., 2010).
There are several modes of survey instrumentation: face-to-face interviews,
telephone interviews, self-administered questionnaires, or a combination of these
approaches. The overall interviewing technique has the advantage of allowing the
interviewer to clarify or restate questions. Probing by the interviewer can also be used to
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clarify answers given by the respondents. One possible disadvantage to interviewing is
the required training that is often needed for the interviewers. Interviewing can be done in
person (face to face) or over the telephone. Face-to-face interviews typically have a high
response rate, allows for the use of visual aids and the making of unobtrusive
observations. However, one disadvantage to face-to-face interviewing is the cost. Costs
may be reduced by using telephone interviews; however, establishing rapport with
respondents is often more difficult. Additionally, complex questions may not be suitable
for telephone interviews. Another mode is self-administered questionnaires via the mail
or electronic means, such as the Internet. This approach is often the least costly of all
approaches and has the advantage of allowing the respondents to complete the item at
their convenience (Singleton et al., 2010). The present study used an online survey
approach.
Summary
In this chapter, the theoretical framework was discussed. This theoretical
framework included social cognitive theory, choice, and agency theory as related to
advertising. Global consumer culture positioning was also discussed in this review.
Research does exist in the overall advertising field of study; however, research specific to
DTCA in comparison is limited. DTCA is a particular type of advertising; its possible
risks may be associated with the use of prescription medications. Several studies have
been conducted by the FDA, with most being experimental in nature. A 2004 study by
the FDA was one of the first studies conducted in this field, and it has been referenced
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frequently in the review of literature. Like the 2004 FDA research, the present study used
the survey method. Other research discussed in this literature review included a content
analysis based on Bandura’s (2001) social cognitive theory. The purpose of the Welch
Cline and Young (2004) study was to identify features of DTCA that could function as
modeling.
Relevant literature covering the history of governmental regulation of the
production and sale of prescription medications, the potential supply and demand side
incentives, as well as the behavioral and agent aspects of consumer drug seeking were
reviewed in developing the theoretical framework. As a comprehensive consideration of
the phenomena associated with DTCA, this literature review and theoretical framework
provided a foundation and balanced understanding of the factors and issues pertinent to
understanding the complexities of suggested associations. This framework established the
premise for the present study and served as the basis for the two specific hypotheses that
were tested. Chapter 3 contains an explanation of how the study was designed. Chapter 4
includes a discussion about the outcomes of the study. Chapter 5 includes discussion,
conclusions, and recommendations for future research.
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Chapter 3: Research Method
Introduction
The purpose of this study was to determine the association between DTCA and
health care-seeking behaviors and to explore patient perspectives on their overall health
care experience. Singleton et al. (2010) defined research, specifically social research, as a
process of first formulating questions and then seeking answers to the questions about a
person’s social environment or surroundings. Both future producers of research and
consumers of research findings benefit from understanding research methods. From the
consumer perspective, research findings are displayed on a daily basis in everyday life.
One example of such use of research is in advertising, in which results from studies and
other forms of research are introduced to encourage the viewer to purchase a specific
product or service. At times, it can be difficult to decipher which advertisements are
presenting misleading information. Therefore, the consumer must listen and understand
the methods that are used in the overall research process.
Generally, the approaches to research are either qualitative or quantitative.
Research designs can also use a combination of both (qualitative and quantitative)
approaches. Additionally, there can be a variety of methods or strategies used with either
approach (Singleton et al., 2010). This section provides details on the research design,
research questions and hypotheses, data collection, data analysis, and theoretical
framework.
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Research Variables
This research study included two types of variables. The independent variables
were patient exposure to advertising as measured by eight questions (see Table 2),
sociodemographic characteristics (i.e., age, gender, income, and ethnicity), health status,
and education. The dependent variable, health care-seeking behaviors, were comprised of
two variables: physician office visits as measured by four questions (see Table 2) and
asking for a prescription as measured by four questions (see Table 2).
Research Hypotheses
The two hypotheses of this study posited that patient exposure to DTCA is
associated with physician office visits. Specifically, Hypothesis 1 related to physician
office visits and exposure to DTCA:
H10: There is no relationship between patient exposure to DTCA and subsequent
physician office visits.
H1a: There is a direct association between patient exposure to DTCA and
subsequent physician office visits.
Hypothesis 2 related to requests for a specific prescription medication and exposure to
DTCA:
H20: There is no relationship between patient exposure to DTCA and a patient
asking subsequently for a corresponding prescription drug.
H2a: There is a direct association between patient exposure to DTCA and a
patient asking subsequently for a corresponding prescription drug.
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Research Design and Approach
In this study, I used a quantitative approach. There are pros and cons to either
(qualitative or quantitative) research design. Denzin and Lincoln (2011) defined
qualitative research as an approach in which the researcher studies factors or events in
their natural settings. The data or material can be collected through a variety of methods,
including case studies, interviews, observations, historical account, or personal
experience. Creswell (2012) presented a list of the characteristics of qualitative research:
•

Natural setting as source of data (the environment in which the observed
event occurs);

•

Researcher as key instrument of data collection

•

Data collected as words or pictures

•

Outcome as process rather than product

•

Analysis of data inductively, attention to particulars

•

Focus on participants’ perspectives, their meaning;

•

Use of expressive language

•

Persuasion by reason. (Creswell, 2012, p. 44)

Quantitative research was described by Marczyk et al. (2010) as involving studies
that use statistical analyses in the process of obtaining findings. Quantitative methods can
also be defined as focusing on strict quantifiable data. In quantitative research, large-scale
sampling procedures are most often used, as well as statistical tests to study averages and
variances of a group (Willig, 2013). The history of quantitative research can be traced
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back to the natural sciences, whereas the qualitative research approach is more related
historically to the human or social sciences. Quantitative research is often represented by
the following characteristics: deductive in nature, is theory-driven, attempts to understand
laws and causes, and is outcome-oriented. In contrast, qualitative research is inductive,
theory-generating, seeks meanings, and is discovery-oriented.
A quantitative survey was used to collect data from participants in the present
study. Specifically, I used the 2004 FDA survey instrument in this study. Marczyk et al.
(2005) claimed that researchers use survey studies to ask questions to a large number of
people. These questions can be used to investigate attitudes, opinions, or specific
behaviors. The findings from surveys may be limited to describing responses, but an
attempt may be made to find a relationship between reported behaviors/opinions and the
respondents’ characteristics. Similarly, Singleton (2010) stated that relationships among
the measure are examined once people answer questions, which is the basic idea of a
survey. Reasons for using this approach vary; however, Fowler (2014) stated that surveys
may be the only means of getting information that is easy, quick, and inexpensive. The
budget of researchers vary and surveys may allow for quick collection of data that is also
less expensive.
Surveys are unique from other means of collecting data. Singleton et al. (2010)
described three features of survey research. First, many surveys consist of a large number
of respondents. To represent the target population, the respondents are selected through
probability sampling. Second, systematic questionnaires or interviews are used as a part
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of the process of asking prearranged questions. These interviews may be structured,
unstructured, or semistructured. The optimal structured interview contains specific
objectives with prearranged questions. Comparatively, in an unstructured interview, the
interviewer may make adaptations. The third feature of surveys consists of the
numerically coding and analyzing of respondents’ answers.
Survey research methods have numerous advantages and disadvantages. One
advantage is that surveys can be an efficient means of gathering data. This approach can
address multiple research questions within one survey. Another advantage is the lower
costs of obtaining data, which can be even less when using secondary analysis of survey
data collected from professional or other resources. There are also several limitations to
survey research. Surveys are less adaptable and systematic measurement error may occur
(Singleton et al., 2010).
Setting and Sample
The survey for this study was available to participants via the university website
and SurveyMonkey. Inclusion criteria for this study consisted of adult college students. A
diverse population of people worldwide was represented by this online university and
SurveyMonkey. According to the U.S. Department of Education (2013), the actual
number of college students in 2010 was 21 million and, for the fall of 2013, it was
projected to be 21.8 million. Published sample size tables, online sample calculators, and
formulas are some of the tools that can be used to determine sample size of a study.
Additionally, the population size, sampling error, and the overall purpose of the study are
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all factors that have an impact on the needed sample size for a study (Cottrell &
McKenzie, 2010).
In this study, I used Cochran’s (1963) formula for calculating sample size:
n = Z2(pq)/e2
where the sample size is n, Z is the appropriate Z score for a confidence interval, p
represents an estimate of the proportion of the attribute in the population, q is 1 - p, and e
is the margin of error or level of precision. A conservative estimate was used, whereas
the value of p was 0.5, given the unknown variability of the attribute (health care-seeking
behaviors), and the margin of error, e, was 10%. The confidence interval of 95% was
used for this study. Using this equation and the projected number of college students
(21.8 million), the suggested minimum sample was 96 participants.
Given the small sample size suggested by Cochran’s (1963) formula, a power
analysis was conducted. Because the alpha level is the probability of incorrectly rejecting
the null hypothesis (Type I error), the alpha level is the chance of incorrectly inferring a
difference where none exists. Beta is the probability of incorrectly rejecting the null
hypothesis (Type II error), or incorrectly inferring no difference where one actually
exists. The power of a test is measured by 1 – beta and therefore relates to Type II errors.
Decreasing the alpha level increases the probability of a Type II error by
decreasing power but increases the confidence in the results by decreasing the probability
of a Type I error. Conversely, increasing the alpha level increases the potential for a Type
1 error and decreases the confidence in the results but decreases the potential for a Type
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II error by increasing power. Because the standard deviation and mean for the population
are unknown, a conservative alpha level of 0.05, medium effect size of 0.30, and power
of 0.95 were used to ensure adequate power and confidence in the results. Using this
information, a power analysis and sample size-determining statistical program called
G*Power version 3.1.9.2 (Faul, Erdfelder, Buchner &, Lang, 2009; Jones & Lentz, 2013)
determined a minimum sample size of 177 to provide statistical power of 0.95. This more
conservative required sample size was used for this study.
Instrumentation and Materials
The survey instrument used in the present study was adapted from a 2004 study
by the FDA. Report findings from the FDA study, the survey, and the dataset were all
available to the public on the FDA.gov website. The FDA survey was conducted
nationally via telephone in 1999 and 2002. These previous surveys were basically
identical, with only slight revisions made for clarification purposes and the inclusion of
health insurance questions. The present study used only 24 questions (relevant to study
variables) from the patient survey, the original of which contained 65 questions. The
survey was divided into the following sections:
1. Survey inclusion: Participants must be 18 or older and have visited a doctor,
nurse practitioner, or a physician’s assistant for a health condition or concern
of his or her own within the last year. This visit was for a concern of the
patient’s own, not for a child or parent or someone else.
2. Awareness of prescription drug advertising: Exposure to advertisements.
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3. Interaction with doctor: Patient type of visit and conversation.
4. Attitude/questions about prescription drug advertising: Overall attitudes about
DTCA.
5. Demographic Information: Education, ethnic group, health insurance, and so
on.
The survey instrument was adapted for the present study. The original study was
conducted via telephone; therefore, adaptations were made to conduct the survey online.
This change allowed participants to select from a list of answer choices online compared,
to responding verbally to questions posed over the telephone. The majority of the survey
questions were measured using Likert scales. Table 2 provides a “crosswalk” of the
variables and the selected questions that were derived from the operational definitions.
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Table 2.
Study Variables and Corresponding Survey Questions
Study variables
Patient exposure

Survey question*
Q3. In the last year, do you recall seeing or hearing any
advertisements for prescription drugs? (Recall DTCA)
Q4.

Yes

No

Have you seen or heard any ads for prescription drugs in any

of the following ways: (Forms of DTCA)
a.

On television

b. On the radio
c.

In a magazine

d. In a newspaper
e.

On the Internet

f. In a letter, flyer, or announcement you got in the mail
g. On an outdoor billboard
h. In a grocery store or pharmacy
i. Anywhere else? (please specify)

Table continues
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Study variables
Patient exposure

Survey question
Q5.

In the last year, how many different prescription drugs do you

recall seeing advertised in any form? (Number of DTCA)

Q6.

None

One

Two

Three

Four

Five

Six

Seven

Eight

Nine

Ten

More than ten

Thinking about the ads you have seen both in print and on

television, has an advertisement for a prescription drug ever caused
you to look for more information, for example, about the drug or
about your health? (Look for more DTCA information) Yes

Q7.

No

What information did you look for? (Type of DTCA

information)
Side effects
Interactions with other drugs/medicines
Dangers of the drug
Cost of the drug
Other__________

Table continues
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Study variables
Patient exposure

Survey question
Q8.

Has an advertisement for a prescription drug ever caused you

to ask a doctor about a medical condition or illness of your own that
you had not talked to a doctor about before? (Ask doctor about
medical condition)

Yes

No

Q15. I like seeing advertisements for prescription drugs. (Like
seeing DTCA)
Agree strongly
Agree somewhat
Neither agree nor disagree
Disagree somewhat
Disagree strongly
Q16. Advertisements for prescription drugs help me make better
decisions about my health. (DTCA help in decision making)
Agree strongly
Agree somewhat
Neither agree nor disagree
Disagree somewhat
Disagree strongly

Table continues
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Study variables
Physician office visits

Survey question
Q1.

How long has it been since the last time you saw a doctor, a

nurse practitioner, or a physician’s assistant where you talked about
a health condition or concern of your own, not for a child or parent
or someone else? (Last Visit)
Within the last week
1 to 4 weeks ago
5 weeks to 3 months ago
4 to 6 months ago
7 to 11 months ago
1 year ago
More than 1 year ago
Never
Q2.

Was this a routine visit, such as a checkup or physical?

(Routine visit) Yes
Q9.

No

Don’t know

At any of the visits to your doctor, did you talk about a

prescription drug? (Talk about prescription) YesNo

Table continues
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Study variables
Physician office visits

Survey question
Q14. Overall, how would you rate your interaction with your doctor
at this visit? (Interaction with doctor)
Excellent
Good
Only fair
Poor

Asking for a

Q10. Did you go to this visit expecting your doctor to prescribe a

prescription

drug for you? (Expect Prescription) Yes No
Q11. At that visit, did you ask whether there might be a prescription
drug to treat you? (Ask about prescription)
Yes

No

Q12. Did you mention an advertisement you saw or heard for a drug
or bring information about the advertised drug with you? (Mention
DTCA)
Yes, I mentioned an ad I saw or heard
Yes, I brought something about the drug with me
Yes, both
No

Table continues
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Study variables

Survey question

Asking for a

Q13. Did your doctor do one or more of the following: (Doctor

prescription

recommendation) [Select all that apply]
Give you the prescription drug you asked about
Not give you the prescription drug you asked about
Recommend a different prescription drug
Recommend an over-the-counter drug
Recommend no drug
Recommend you make changes in behavior or lifestyle
Something else (specify)

Sociodemographics

Q17. Overall, would you say your health is: (Health Status)
Excellent Very good
Fair

Good

Poor

Q18. How many hours in a typical week do you use the Internet or
World Wide Web at home and at work? (Use of Internet or World
Wide Web).
___________________ Do not have a computer.
Q19. Gender (Gender): Male

Female

Table continues
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Study variables
Sociodemographics

Survey question
Q20. What is your marital status? (Marital Status)
Married

Single

Widowed

Divorced

Separated

Q21. What is the last grade of school that you completed?
(Education)
Grade school or less

Some high school

Completed high school

Some college

Completed college

Graduate school or more

Other beyond high school (business, technical, etc.)
Q22. Are you of Hispanic, Latino, or Spanish origin? (Hispanic
origin)
No, not of Hispanic, Latino, or Spanish origin
Yes, Mexican, Mexican American, Chicano
Yes, Puerto Rican
Yes, Cuban
Yes, another Hispanic, Latino, or Spanish origin – Please state
origin, for example Argentinean, Colombian, Dominican,
Nicaraguan, Salvadoran, and so on ____________________.

Table continues
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Study variables
Sociodemographics

Survey question
Q23. What is your race? (Race) Select one or more
White

Black, African American, or Negro

American Indian or Alaska Native Asian Indian
Chinese

Filipino

Japanese

Korean

Vietnamese

Other Asian – (For example Laotian, Thai, Pakistani,
Cambodian, and so on) _______________________.
Native Hawaiian
Samoan

Guamanian or Chamorro
Other race __________________.

Q24. What year were you born? (Age) _________

Note. An abbreviation for each question is presented in parentheses.

Reliability and Validity
Validity refers to the extent to which an instrument measures what it is purported
to measure (Leedy & Ormrod, 2013). There are no statistical tests for validity, but an
instrument is considered valid when the researcher reaches the opinion that the
instrument is measuring what it was designed to measure. There are several types of
validity (criterion, content, and construct). Criterion validity checks the performance of
an instrument to outcomes that are already held to be valid. Content validity considers
where the instruments items are logically associated with the phenomenon to be
measured. According to Cronbach and Meehl (1955), “construct validity must be
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investigated whenever no criterion or universe of content is accepted as entirely adequate
to define the quality to be measured” (p. 282). In addition to FDA assurances of survey
validity from their use of the instrument for other studies, the questions or variables were
compared to other drug advertising research in peer-reviewed journals as an assessment
of content and construct validity (Bhutada et al., 2013). Because the questions were direct
and were not intended to measure complex psychometric concepts such as personality,
trust, mental capacity, or quality of life, face validity was determined by comparing the
question to the applicable operational definition to ensure congruency.
Leedy and Ormrod (2013) described reliability as referring to the extent to which
an instrument produces consistent results on repeated tests. Reliability of an instrument is
closely associated with its validity; however, an instrument cannot be valid unless it is
reliable (Tavakol & Dennick, 2011).
The present study used Cronbach’s alpha to measure reliability with the following
formula:
α = Nρ / [1 + ρ(N - 1)]
where N is equal to the number of items and ρ is equal to the mean inter-item correlation.
This calculation is expressed between 0 and 1 and is a measure of the internal consistency
of a test/scale. No pilot testing was performed; however, researchers who developed,
validated, and used the survey instrument in the 2004 FDA study reported a reliability
coefficient of α = .71 when using three items for doctor-patient interaction.
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Data Collection
Approval from the institution review board (IRB) was obtained prior to uploading
the study to the participant pool and SurveyMonkey. Once uploaded and approved, a
mass e-mail informing the college community of the study, as well as a link to the survey,
was distributed by the college and SurveyMonkey. Participants were able to access the
survey anonymously. Based upon the 15-minute collection time reported by the FDA
(HHS, 2004), it was anticipated that participants would take approximately 5–8 minutes
to complete this online survey. The survey was made available for several weeks to reach
the target sample. A total of 235 participants completed the survey.
Data Analysis
The present study was quantitative and the data were analyzed using descriptive
statistics and analyses of variance (ANOVAs), which were employed to test the
hypotheses of this study. Descriptive statistics are used in research to summarize data and
numerically describe variables. Inferential statistics, in contrast, are used to make an
assumption about a population based upon the sample (McNabb, 2013).
With each analysis, statistical significance and predictive value were assessed, as
applicable. A two-step technique was used, as applicable. First, the independent variables
and the dependent variable were loaded into an ANOVA to determine the predictive
power of the equation. Next, the applicable sociodemographic variable(s) were loaded
into an equation with the dependent variable to assess the impact of the variable(s).
Finally, the predictive power of the two equations were compared to determine the
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predictive value of DTCA. Statistical Package for the Social Sciences (SPSS), Version
21, was used for all data analyses. Given that multiple tests would be run on the data, the
Bonferroni correction was used to control the family-wise error rate. Although considered
conservative, this correction seeks to maintain an acceptable probability of false positives
and false negatives by adjusting the p value to a level more stringent than 0.05. An
ANOVA can be used to determine if the considered means are different and the
Bonferroni correction helps to identify specifically which means are different. Using
SPSS Version 21, statistical significance was assessed at the p < 0.025 level, given the
more stringent level required by the Bonferroni correction. This value was derived by
dividing the traditional alpha level of 0.05 by the number of hypotheses being tested
(0.05/2=0.025; Jiang, Barmada, Cooper, & Becich, 2011; Patel, Chen, Kodama, Ioannidis
& Butte, 2012; Pollak, Jones, Castillo, Bosse, & MacKenzie, 2010).
The 2004 FDA study sought to assess patient awareness of and opinions about
DTCA efforts, and patients’ processes for obtaining more information and asking
questions. As a largely descriptive study, few inferential assertions were included in the
original study. The present study used the raw data obtained from the FDA survey for
comparative purposes. A sociodemographic profile of the survey respondents for the
1999 and 2002 surveys is presented in Table 3. The highest proportion of respondents
were between 35 and 54 years of age (43%/40%), female (65%/65%), White/Caucasian
(77%/79%), with incomes of less than $50,000 (53%/53%), completed college or more
(40%/40%), were married (56%/58%), and reported believing that their health status was
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excellent/very good (56%/51%). The stark sociodemographic similarities between the
two surveys and society at large support the reliability of the employed sampling
techniques. The present study had 235 respondents, with characteristics shown in Table
4. Chapter 4 provides more details regarding study respondents.
Theoretical Model
This research used a theoretical framework consisting of social learning theory,
information integration theory, and prospect theory to examine consumer behavior as it
relates to DTCA of prescription drugs. The 2004 study by Welch Cline & Young
conducted a content analysis based on Bandura’s social learning theory. The purpose of
the Welch Cline & Young study was to identify features of DTCA that may function as
modeling. Visual cues were examined as vicarious motivators. Bandura’s social learning
theory describes that when a behavior is observed the possible observed rewards can
become motivators. Specifically, in DTCA cures, happy or healthy product users are
motivators. Welch Cline & Young concluded that change in health care behavior might
be triggered by DTCA. Consumers are often exposed to visual models with positive
features, such being active and friendly.
The fundamental concept of integration theory is that the way a person thinks or
behaves depends on multiple stimuli acting in cooperation with one another. Integration
function combines the transformed psychological stimuli into an implicit response, which
is then externalized using the response function. A person uses simple algebraic rules on
the stimulus information before producing a response (Anderson, 2014).
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Table 3.
Sociodemographics of FDA (HHS, 2004) Survey Respondents
1999 (N = 960)

2002 (N = 944)

%

n

%

n

18–24

7

69

7

65

25–34

17

155

15

140

35–44

23

218

18

171

45–54

20

196

22

208

55–64

14

131

17

164

65+

20

191

21

196

Male

35

334

35

327

Female

65

626

65

616

Respondents
Age

Gender

Table continues
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1999 (N = 960)

2002 (N = 944)

%

n

%

n

American Indian/Alaska Native

4

34

4

34

Asian/Pacific Islander

3

25

2

23

12

116

10

99

4

43

4

36

77

742

79

747

Less than $20,000

20

189

19

185

$20,000–less than $34,999

17

162

17

161

$35,000–less than $49,999

16

153

17

158

$50,000–less than $74,999

14

132

18

166

$75,000+

16

155

20

191

Completed high school or less

36

341

39

366

Some college

24

226

21

201

Completed college or more

40

388

40

375

56

534

58

550

Respondents
Ethnicity (multiple responses permitted)

Black/African American
Hispanic/Latino
White (Caucasian)
Income

Education

Marital status
Married

Table continues
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1999 (N = 960)

2002 (N = 944)

%

n

%

n

Single

22

212

21

197

Widowed

10

100

9

83

Divorced

9

84

10

95

Separated

3

27

2

16

Excellent/very good

56

536

51

481

Good/fair/poor

44

421

49

463

Respondents

Health status

Prospect theory similarly examines how one makes decisions. Prospect theory
attempts to describe decisions that are made among alternatives where risk is involved
(Nickerson, 2012). The knowledge and understanding required to make safe and
appropriate medication decisions is so advanced that the general public must rely on the
expertise of physicians to determine the appropriateness and authority to obtain and
consume some high-risk medications (Pardun, 2014). In agency theory, this agency
relationship moderates the conditioning, learning, integration of information, and
prospect decisions of the average person. Within this theoretical model, it is suggested
that patients, regardless of their sociodemographic profile, seek to engage their agent in
their desire to be considered for or obtain prescription medications.
To summarize the theoretical model, social learning theory considers
environmental influences on behavior. In the present study, DTCA is considered an
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environmental influence on patient behavior. Information integration theory considers the
interaction of multiple stimuli on behavior. In the present study, DTCA is considered a
stimulus affecting patient behavior. Prospect theory suggests that individuals engage in
beneficial decision making, ensuring that gains are greater than losses. In this study,
DTCA helped individuals draw conclusions about gains and losses in terms of their
health. All these theories about individual behavior must be considered within the context
of agency theory because only doctors can prescribe prescription medications and
patients are generally less educated about health care than their doctors. Therefore,
doctors act in an agent role on behalf of their patient.
Protection of Participants
The university IRB oversees all proposals to maintain participant rights and
protections. The IRB ensured that the methods of data collection for this study presented
minimal risk to participants, complied with ethical principles, and met confidentiality
requirements. Participation in this study was voluntary. Participants had the right to
withdraw from the study at any time during the study process. Additionally, participants
had the right to ask questions during the survey process or afterwards. No incentives were
given for participation in this study. Approval from the IRB was obtained before data
collection began.
Summary
The purpose of this study was to determine the association between DTCA and
health care-seeking behaviors and to explore patient perspectives on the issue relative to
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patients’ overall health care experience. This research used a theoretical framework
consisting of social learning theory, information integration theory, and prospect theory
to examine consumer behavior as it related to DTCA of prescription drugs. This research
study included two types of variables. The independent variables were patient exposure
to advertising, sociodemographic characteristics (i.e., age, gender, income, and ethnicity),
health status, and education. The dependent variable, health care-seeking behaviors, was
the summary of two variables: physician office visits and asking for a prescription. The
two research hypotheses of this study posited that patient exposure to DTCA was
associated with physician office visits.
This study uses a quantitative approach however; there are pros and cons to either
design method. The survey instrument that was used was taken from the 2004 study
conducted by the FDA. This instrument was made available to participants in the present
study via the university website and SurveyMonkey. Approximately 5,000 individuals
were included in the overall university participant pool. Inclusion criteria for this study
consisted of adult students who had seen a doctor, a nurse practitioner, or a physician’s
assistant for a condition or concern of his or her own in the past year. A diverse
population of people worldwide was represented in this online university. Data were
analyzed using descriptive statistics and ANOVAs, which were employed to test the
hypotheses of this study. The Bonferroni correction was used to control the family-wise
Type I error rate. With each analysis, statistical significance and predictive value were
assessed, as applicable. A two-step technique was used, as applicable. Approval from the
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university IRB was obtained prior to the data collection process. The results of the
analyses of the collected data are presented in Chapter 4.
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Chapter 4: Results
Introduction
The purpose of this study was to determine the association between DTCA and
health care-seeking behaviors and to explore patient perspectives on patients’ overall
health care experience. Two research questions acted as a catalyst for this study:
1.

What is the relationship between direct-to-consumer advertising (DTCA)
and physician office visits?

2.

What is the relationship between direct-to-consumer advertising (DTCA)
and patients asking for a prescription?

These questions were researched through two hypotheses. Hypothesis 1 related to
physician office visits and exposure to DTCA:
H10: There is no relationship between patient exposure to DTCA and subsequent
physician office visits.
H1a: There is a direct association between patient exposure to DTCA and
subsequent physician office visits.
Hypothesis 2 related to requests for a specific prescription medication and exposure to
DTCA:
H20: There is no relationship between patient exposure to DTCA and a patient
asking subsequently for a corresponding prescription drug.
H2a: There is a direct association between patient exposure to DTCA and a
patient asking subsequently for a corresponding prescription drug.
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The data were collected via an online survey and were analyzed with the
statistical program SPSS, Version 21. This chapter includes a presentation of the
collected data, an analysis of the findings, and summarized results.
Data Collection
Data were collected via an online survey posted on two survey websites, a
university website participant pool and on SurveyMonkey. The collected data were
analyzed with SPSS using ANOVAs, which were employed to test the hypotheses of this
study. The statistical significance and predictive value were assessed, as applicable.
After receiving approval from the IRB, the survey was uploaded to the university
website for access by an online participant pool. A mass e-mail list of newly posted
studies for that month was sent to inform the college community. Interested participants
were then able to register (if needed) to use the site and then access the anonymous
survey instrument via this online participant pool. The survey was made available for 4
weeks with few participants (five). To reach the target sample of 96 participants, the
survey was made available for an additional 3 months, for a total of 132 days. Still, only
30 participants had accessed and taken the survey via the online participant pool. To
obtain additional participants, I engaged the services of SurveyMonkey to assist in
obtaining additional participants who met the criteria of at least 18 years of age and a
current student.
This study remained a focus of an academic community; therefore, the criteria
remained unchanged. According to the U.S. Department of Education (2013), the actual
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number of college students in 2010 was 21 million and, for the fall of 2013, was
projected to be 21.8 million. Maintaining a confidence level of 95% and a confidence
interval of 10, the sample size remained at 96 participants. Prior approval was obtained
from the IRB to make this procedural change of posting on SurveyMonkey.
SurveyMonkey participants received the same invitation/consent forms and were offered
the survey to complete online. The survey consisted of 24 questions (eight questions used
to assess patient exposure, four questions for physician office visits, four questions for
asking for a prescription, and eight sociodemographic questions). There were 205
respondents via SurveyMonkey. Data from the participant pool and SurveyMonkey were
combined and analyzed for a total of 235 participants. The sociodemographic profile of
participants in this survey was also compared to the profile of the participants in the FDA
(HHS, 2004) 2002 survey. To minimize the number of deleted cases in each analysis,
pairwise deletion was used to address missing completely at random data (Baraldi &
Enders, 2010).
Descriptive Statistics
The survey was opened for volunteers for approximately 8 months. A total of 89
male students (38%) and 144 female students (62%) participated. The 2002 FDA survey,
although having a larger sample size (944), had a similar composition of 35% male
participants and 65% female participants, as shown in Table 4. All participants were over
18-years-old, with 90 (38.3%) between 18- and 24-years-old, 59 (25.1%) between the
ages of 25 and 34, 27 (11.5%) between the ages of 35 and 44, 16 (6.8%) between the ages

97
of 45 and 54, and 13 (5.6%) over 55 years of age. By comparison, there were a larger
number of older respondents in the original FDA (HHS, 2004) survey, with 58% being
over the age of 45. The ethnicities of respondents in both the present study and the FDA
survey were similar: 79% were White/Caucasian American for the FDA survey and
80.5% for this survey. However, respondents to the original FDA survey showed a higher
percentage of being married at 58%, compared to 28% in this study. Table 3 represents
the sociodemographic characteristics of participants in the original FDA survey. Table 4
shows a summary of the respondent’s sociodemographic data for this study.
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Table 4.
Respondent Sociodemographics (N = 235)
Sociodemographic

%

n

18-24

38.3

90

25-34

25.1

59

35-44

11.5

27

45-54

6.8

16

55-64

4.3

10

65+

1.3

3

Age

Gender
Male

38

89

Female

62

144

American Indian/Alaska Native

3

7

Asian/Pacific Islander

1.3

3

Black/African American

9.5

22

Hispanic/Latino

6

14

80.5

186

Ethnicity (multiple responses permitted)

White (Caucasian)

Table continues
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Sociodemographic

%

n

$0–$24,999

24.9

51

$25,000–$49,999

18

37

$50,000–$99,999

24.9

51

$100,000–$149,999

12.2

25

$150,000+

20

41

Income

Education
Completed high school or less

7.4

15

Some college

46

94

Completed college or more

46.6

95

Married

28

66

Single

60

140

Marital status

Widowed

1.3

3

Divorced

9.4

22

Separated

0.9

2

Health status
Excellent/very good

58

136

Good/fair/poor

42
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Explanation of Tables
SPSS Version 21 was the statistical program used to perform ANOVAs. ANOVA
determines if there is a significant difference between the means of at least two
independent variables or groups. The results were grouped by the applicable hypothesis.
Results are presented in the following ANOVA tables with abbreviated question titles.
The corresponding full-text survey questions are presented in Table 2.
Hypothesis 1
Hypothesis 1 related to physician office visits and exposure to DTCA:
H10: There is no relationship between patient exposure to DTCA and subsequent
physician office visits.
H1A: There is a direct association between patient exposure to DTCA and
subsequent physician office visits.
Patient exposure to DTCA was associated with several aspects of physician office
visits. As shown in Table 5, seeing an advertisement for prescription drugs was
associated with rating the interaction with a doctor as positive [F = (1, 229) = 15.94, p =
0.00]. There were no statistically significant differences (p < 0 .025) between seeing an
advertisement for prescription drugs and more recent visits to a doctor, a nonroutine visit,
and talking to doctor about a prescription drug.
The number of different prescription drug advertisements that were seen over the
past year was associated with rating the interaction with a doctor as positive [F = (11,
218) = 2.09, p = 0.02], as shown in Table 6. There were no statistically significant
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differences (p < 0.025) between the number of different prescription drug advertisements
that were seen over the past year and talking to a doctor about a prescription drug, the
timing of the last office visit, or the type of visit (routine or nonroutine).
Analytical results in Table 7 demonstrate that viewing a prescription drug
advertisement that caused a search for more information was associated with a more
recent visit to a doctor, nurse practitioner, or physician’s assistant [F = (1,228) = 8.05, p
= 0.01], and talking to a doctor about a prescription drug [F = (1,231) = 34.70, p = 0.00].
There were no statistically significant differences (p < 0 .025) between viewing a
prescription drug advertisement that caused a search for more information and a
nonroutine visit or rating the interaction with a doctor.
As shown in Table 8, there were no statistically significant differences (p < 0
.025) between looking for additional information (side effects, interactions with other
drugs/medicines, dangers, and/or costs) and the timing of the last visit, type of visit,
talking to doctor about prescription, or rating the interaction with the doctor.
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Table 5.
One-Way ANOVA for Physician Office Visits: Question 3, Recall DTCAs
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Rate interaction

Factor
Between groups

squares

Mean
df

square

.138

1

.138

Within groups

891.086

230

3.874

Total

891.224

231

.053

1

.053

Within groups

61.566

229

.269

Total

61.619

230

.335

1

.335

Within groups

57.945

233

.249

Total

58.281

234

8.086

1

8.086

Within groups

116.148

229

.507

Total

124.234

230

Between groups

Between groups

Between groups

F

Sig.

.036

.850

.199

.656

1.349

.247

15.942

.000*

Note. Significance was assessed at the *p < 0.025 level. Last visit, routine visit, talk
about Rx, and rate interaction correspond to survey questions 1, 2, 9 and 14 respectively,
as all survey questions are displayed in Table 2.
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Table 6.
One-Way ANOVA for Physician Office Visits: Question 5, Number of DTCAs
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Rate interaction

Factor

Mean

squares

df

square

45.415

11

4.129

Within groups

845.809

220

3.845

Total

891.224

231

1.685

11

.153

Within groups

59.934

219

.274

Total

61.619

230

5.013

11

.456

Within groups

52.970

222

.239

Total

57.983

233

Between groups

11.683

11

1.062

Within groups

110.648

218

.508

Total

122.330

229

Between groups

Between groups

Between groups

F

Sig.

1.074

.384

.560

.860

1.910

.039*

2.093

.022*

Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey
questions 1, 2, 9 and 14 respectively, as all survey questions are displayed in Table 2.
Significance was assessed at the *p < 0.025 level.
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Table 7.
One-Way ANOVA for Physician Office Visits: Question 6, Look for More DTCA
Information
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Rate interaction

Factor
Between groups

squares

Mean
df

square

29.913

1

29.913

Within groups

847.569

228

3.717

Total

877.483

229

1.119

1

1.119

Within groups

60.042

227

.265

Total

61.162

228

7.546

1

7.546

Within groups

50.231

231

.217

Total

57.777

232

.143

1

.143

Within groups

123.307

227

.543

Total

123.450

228

Between groups

Between groups

Between groups

F

Sig.

8.047

.005*

4.232

.041*

34.702

.000*

.263

.608

Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey
questions 1, 2, 9 and 14 respectively, as all survey questions are displayed in Table 2.
Significance was assessed at the *p < 0.025 level.
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Table 8.
One-Way ANOVA for Physician Office Visits: Question 7, Type of DTCA Information
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Rate interaction

Factor
Between groups

squares

Mean
df

square

3.515

2

1.758

Within groups

887.709

229

3.876

Total

891.224

231

1.410

2

.705

Within groups

60.209

228

.264

Total

61.619

230

.718

2

.359

Within groups

57.563

232

.248

Total

58.281

234

1.543

2

.772

Within groups

122.691

228

.538

Total

124.234

230

Between groups

Between groups

Between groups

F

Sig.

.453

.636

2.670

.071

1.447

.237

1.434

.241

Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey
questions 1, 2, 9 and 14 respectively, as all survey questions are displayed in Table 2.
Significance was assessed at the *p < 0.025 level.
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Viewing a prescription drug advertisement that caused a search for more
information was associated with a more recent visit to a doctor, nurse practitioner, or
physician’s assistant [F = (1,228) = 8.05, p = 0.01], and talking to a doctor about a
prescription drug [F = (1,231) = 34.70, p = 0.00], as shown in Table 9. There were no
statistically significant differences (p < 0 .025) between viewing a prescription drug
advertisement that caused a search for more information and a nonroutine visit, the type
of visit or how the interaction with the doctor was rated.
As shown in Table 10, agreeing that advertisements for prescription drugs help
make better decisions about health was associated with talking to a doctor about a
prescription drug [F = (4,230) = 2.94, p = 0.02]. However, there were no statistically
significant differences (p < 0 .025) between agreeing that advertisements for prescription
drugs help make better decisions about health and the timing of the last office visit, the
type of visit, or the rating for interaction with a doctor.
Several sociodemographic variables were associated with more physician office
visits. Better self-reported health status was associated with rating the interaction with a
doctor as positive [F = (4,226) = 4.20, p = 0.00], as shown in Table 11. There were no
statistically significant differences (p < 0 .025) between the self-reported health status
and not talking to a doctor about a prescription drug, timing of the last visit or the type of
visit.
In Table 12, being a male participant was associated with a more recent visit [F =
(1,228) = 9.31, p = 0.00] and talking to a doctor about a prescription drug [F = (1,231) =
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7.69, p = 0.01]. There were no statistically significant differences (p < 0 .025) between
being male participant and the type of visit or rating the interaction with the doctor.
As shown in Table 13, being married was associated with talking to a doctor
about a prescription drug [F = (4,228) = 3.23, p = 0.01]. There were no statistically
significant differences (p < 0 .025) between marital status and the timing of the last visit,
the type of visit, or rating the interaction with the doctor.
As shown in Table 14, a lower education level was associated with talking to a
doctor about a prescription drug [F = (6, 227) = 3.34, p = 0.00]. There were no
statistically significant differences (p < 0 .025) between education and the timing of the
last visit, the type of visit, or rating the interaction with the doctor.
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Table 9.
One-Way ANOVA for Physician Office Visits: Question 8, Ask Doctor About Medical
Condition
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Factor
Between groups

df

square

19.065

1

19.065

Within groups

857.404

226

3.794

Total

876.469

227

.154

1

.154

Within groups

60.542

225

.269

Total

60.696

226

3.606

1

3.606

229

.234

Between groups

Between groups
Within groups
Total

Rate interaction

squares

Mean

53667
57.273

230

.376

1

.376

Within groups

122.540

225

.545

Total

122.916

226

Between groups

F

Sig.

5.025

.026*

.574

.450

15.387

.691

.000*

.407

Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey
questions 1, 2, 9 and 14 respectively, as all survey questions are displayed in Table 2.
Significance was assessed at the *p < 0.025 level.
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Table 10.
One-Way ANOVA for Physician Office Visits: Question 16, DTCA Help in Discussion
Making
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Rate interaction

Factor
Between groups

squares

Mean
df

square

27.098

4

6.775

Within groups

864.126

227

3.807

Total

891.224

231

.355

4

.089

Within groups

61.264

226

.271

Total

61.619

230

2.836

4

.709

Within groups

55.445

230

.241

Total

58.281

234

1.003

4

.251

Within groups

123.231

226

.545

Total

124.234

230

Between groups

Between groups

Between groups

F

Sig.

1.780

.134

.327

.860

2.941

.021*

.460

.765

Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey
questions 1, 2, 9 and 14 respectively, as all survey questions are displayed in Table 2.
Significance was assessed at the *p < 0.025 level.
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Table 11.
One-Way ANOVA for Physician Office Visits: Question 17, Health Status
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Rate interaction

Factor
Between groups

squares

Mean
df

square

29.197

4

7.299

Within groups

862.027

227

3.797

Total

891.224

231

1.059

4

.265

Within groups

60.560

226

.268

Total

61.619

230

2.425

4

.606

Within groups

55.856

230

.243

Total

58.281

234

8.598

4

2.149

Within groups

115.636

226

.512

Total

124.234

230

Between groups

Between groups

Between groups

F

Sig.

1.922

.108

.988

.415

2.497

.044*

4.201

.003*

Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey
questions 1, 2, 9 and 14 respectively, as all survey questions are displayed in Table 2.
Significance was assessed at the *p < 0.025 level.
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Table 12.
One-Way ANOVA for Physician Office Visits: Question 19, Gender
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Rate interaction

Factor
Between groups

squares

Mean
df

square

34.571

1

34.571

Within groups

846.250

228

3.712

Total

880.822

229

.066

1

.066

Within groups

61.052

227

.269

Total

61.118

228

1.865

1

1.865

Within groups

55.998

231

.242

Total

57.863

232

.161

11

.161

Within groups

123.542

227

.544

Total

123.703

228

Between groups

Between groups

Between groups

F

Sig.

9.314

.003*

.244

.622

7.694

.006*

.296

.587

Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey
questions 1, 2, 9 and 14 respectively, as all survey questions are displayed in Table 2.
Significance was assessed at the *p < 0.025 level.
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Table 13.
One-Way ANOVA for Physician Office Visits: Question 20, Marital Status
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Rate interaction

Factor
Between groups

squares

Mean
df

square

18.280

4

4.570

Within groups

871.911

225

3.875

Total

890.191

229

.478

4

.119

Within groups

60.913

225

.271

Total

61.391

229

3.107

4

.777

Within groups

54.756

228

.240

Total

57.863

232

2.579

4

.645

121.125

224

.541

1243.703

228

Between groups

Between groups

Between groups
Within groups
Total

F

Sig.

1.179

.321

.441

.779

3.234

.013*

1.192

.315

Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey
questions 1, 2, 9 and 14 respectively, as all survey questions are displayed in Table 2.
Significance was assessed at the *p < 0.025 level.
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Table 14.
One-Way ANOVA for Physician Office Visits: Question 21, Education
Sum of
Visit/purpose
Last visit

Routine visit

Talk about Rx

Rate interaction

Factor
Between groups

squares

Mean
df

square

20.631

5

4.126

Within groups

870.079

225

3.867

Total

890.710

230

1.524

5

.305

Within groups

59.867

224

.267

Total

61.391

229

4.705

6

.784

Within groups

53.367

227

.235

Total

58.073

233

3.011

6

.502

Within groups

120.833

223

.542

Total

123.843

229

Between groups

Between groups

Between groups

F

Sig.

1.067

.379

1.140

.340

3.336

.004*

.926

.477

Note. Last visit, routine visit, talk about Rx, and rate interaction correspond to survey
questions 1, 2, 9 and 14 respectively, as all survey questions are displayed in Table 2.
Significance was assessed at the *p < 0.025 level.
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Hypothesis 2
Hypothesis 2 related to requests for a specific prescription medication and
exposure to DTCA:
H20: There is no relationship between patient exposure to DTCA and a patient
asking subsequently for a corresponding prescription drug.
H2A: There is a direct association between patient exposure to DTCA and a
patient asking subsequently for a corresponding prescription drug.
Patient exposure to DTCA was associated with patients asking for a prescription
drug. As shown in Table 15, there were no statistically significant differences (p < 0 .025)
for seeing or hearing advertisements and asking whether there might be a prescription
drug to treat the patient/survey participant, the expectation for a prescription, the
mentioning of an advertisement, or to the doctor’s outcome.
The number of different prescription drug advertisements that were seen was
associated with expecting a doctor to prescribe a drug [F = (11,219) = 3.31, p = 0.00] and
a doctor giving a prescription, recommending a prescription, recommending an over-thecounter drug, or recommending a behavior or lifestyle change [F = (11,222) = 2.23, p =
0.01], as shown in Table 16. However, there were no statistically significant differences
(p < 0 .025) between the number of different prescription drug advertisements and asking
whether there might be a prescription drug to treat the patient/survey participant or
mentioning a prescription drug advertisement that was seen or heard.
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As shown in Table 17, seeing an advertisement for a prescription drug in print or
on television that caused a patient/survey participant to look for more information was
associated with expecting a doctor to prescribe a drug [F = (1,228) = 16.25, p = 0.00],
asking whether there might be a prescription drug to treat the patient/study participant [F
= (1,226) = 43.23, p = 0.00], mentioning a prescription drug advertisement that was seen
or heard [F = (1,229) = 43.33, p = 0.00], and a doctor giving a prescription,
recommending a prescription, recommending an over-the-counter drug, or recommending
a behavior or lifestyle change [F = (1,231) = 37.51, p = 0.00].
As shown in Table 18, looking for side effects, interactions, dangers, or cost
information about a prescription drug was associated with mentioning a prescription drug
advertisement that was seen or heard [F = (2,230) = 7.76, p = 0.00] and a doctor giving a
prescription, recommending a prescription, recommending an over-the-counter drug, or
recommending a behavior or lifestyle change [F = (2,232) = 14.90, p = 0.00]. There were
no statistically significant differences (p < 0 .025) between looking for side effects,
interactions, dangers, or cost information about a prescription drug and expecting a
doctor to prescribe a drug or asking whether there might be a prescription drug to treat
the patient/survey participant.
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Table 15.
One-Way ANOVA for Prescription Request: Question 4, Forms of DTCA
Sum of
Behavior
Expect Rx

Might Rx

Mention ad

Factor
Between groups

squares

Mean
df

square

2.240

8

.280

Within groups

54.204

223

.243

Total

56.444

231

3.608

8

.451

Within groups

50.953

221

.231

Total

54.561

229

.930

8

.116

Within groups

24.461

224

.109

Total

25.391

232

Between groups

Between groups

Did Dr.

Between groups

give Rx

Within groups
Total

5,445

8

.681

169.746

226

.751

175.191

234

F

Sig.

1.152

.330

1.956

.053*

1.064

.389

.906

.512

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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Table 16.
One-Way ANOVA for Prescription Request: Question 5, Number of DTCAs
Sum of
Behavior

squares

df

8.031

11

.730

Within groups

48.238

219

.220

Total

56.268

230

3.723

11

.338

Within groups

50.687

217

.234

Total

54.410

228

1.195

11

.109

Within groups

23.425

220

.106

Total

24.621

231

Did Dr.

Between groups

17.448

11

1.586

give Rx

Within groups

157.714

222

.710

Total

175.162

233

Expect Rx

Might Rx

Mention ad

Factor

Mean

Between groups

Between groups

Between groups

square

F

Sig.

3.314

.000*

1.449

.153

1.021

.429

2.233

.014*

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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Table 17.
One-Way ANOVA for Prescription Request: Question 6, Look for More DTCA
Information?
Sum of
Behavior
Expect Rx

Factor

df

square

F
16.24

.000*

43.233

.000*

43.332

.000*

37.510

.000*

3.731

1

3.731

Within groups

52.361

228

.230

Total

56.091

229

8.677

1

8.677

Within groups

45.358

226

.201

Total

54.035

227

4.035

1

4.035

Within groups

21.324

229

.093

Total

25.359

230

Did Dr.

Between groups

24.000

1

24.000

give Rx

Within groups

147.802

231

.640

Total

171.803

232

Might Rx

Mention ad

Between groups

squares

Mean

Between groups

Between groups

Sig.

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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Table 18.
One-Way ANOVA for Prescription Request: Question 7, Type of DTCA Information?
Sum of
Behavior
Expect Rx

Factor

df

square

1.728

2

.864

Within groups

54.716

229

.239

Total

56.444

231

1.474

2

.737

Within groups

53.087

227

.234

Total

54.561

229

1.604

2

.802

Within groups

23.786

230

.103

Total

25.391

232

Did Dr.

Between groups

19.938

2

9.969

give Rx

Within groups

155.254

232

.669

Total

175.191

234

Might Rx

Mention ad

Between groups

squares

Mean

Between groups

Between groups

F

Sig.

3.615

.028*

3.152

.045*

7.757

.001*

14.897

.000*

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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ANOVA results shown in Table 19 indicate that a prescription drug advertisement
that caused a patient to ask a doctor about a new medical condition or illness was
associated asking whether there might be a prescription drug to treat the patient/study
participant [F = (1,224 ) = 31.98, p = 0.00], mentioning a prescription drug advertisement
that was seen or heard [F = (1,227) = 64.90, p = 0.00], and a doctor giving a prescription,
recommending a prescription, recommending an over-the-counter drug, or recommending
a behavior or lifestyle change [F = (1,229) = 23.60, p = 0.00]. However, there were no
statistically significant differences (p < 0 .025) for expecting a doctor to prescribe a drug.
Liking to see prescription drug advertisements was associated with asking
whether there might be a prescription drug to treat the patient/study participant [F =
(4,223) = 4.53, p = 0.00] and mentioning a prescription drug advertisement that was seen
or heard [F = (4,226) = 9.19, p = 0.00], as shown in Table 20. However, there were no
statistically significant differences (p < 0 .025) between liking to see prescription drug
advertisements and expecting a doctor to prescribe a drug or for the doctor giving a
prescription, or recommending a behavior or lifestyle change.
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Table 19.
One-Way ANOVA for Prescription Request: Question 8, Ask Doctor About Medical
Condition
Sum of
Behavior
Expect Rx

Factor

df

square

.856

1

Within groups

54.877

226

Total

55.732

227

6.684

1

6.684

Within groups

46.824

224

.209

Total

53.509

225

5.631

1

5.631

Within groups

19.696

227

.087

Total

25.328

228

Did Dr.

Between groups

16.043

1

16.043

give Rx

Within groups

155.706

229

.680

Total

171.749

230

Might Rx

Mention ad

Between groups

squares

Mean

Between groups

Between groups

.856

F

Sig.

3.524

.062

31.977

.000*

64.899

.000*

23.595

.000*

.243

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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Table 20.
One-Way ANOVA for Prescription Request: Question 15, Like Seeing DTCA
Sum of
Behavior
Expect Rx

Might Rx

Mention ad

Factor
Between groups

squares

Mean
df

square

1.734

4

.433

Within groups

54.358

225

.242

Total

56.091

229

4.077

4

1.019

Within groups

50.182

223

.225

Total

54.259

227

3.549

4

.887

Within groups

21.810

226

.097

Total

25.359

230

5.775

4

1.444
.734

Between groups

Between groups

Did Dr.

Between groups

give Rx

Within groups

167.359

228

Total

173.133

232

F

Sig.

1.794

.131

4.530

.002*

9.193

.000*

1.967

.100

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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Agreeing that advertisements for prescription drugs help make better decisions
about health was associated with asking whether there might be a prescription drug to
treat the patient/study participant [F = (4,225) = 4.08, p = 0.00] and mentioning a
prescription drug advertisement that was seen or heard [F = (4,228) = 6.68, p = 0.00], as
shown in Table 21. However, no statistically significant differences (p < 0 .025) were
found between agreeing that advertisements for prescription drugs help make better
decisions about health and expecting a doctor to prescribe a drug or for the doctor giving
a prescription, or recommending a behavior or lifestyle change.
Several sociodemographic variables were associated with patients asking for
prescription drugs. As shown in Table 22, better self-reported health status was
associated with not mentioning a prescription drug advertisement that was seen or heard
[F = (4,228) = 4.19, p = 0.00] and a doctor not giving a prescription, recommending a
prescription, recommending an over-the-counter drug, or recommending a behavior or
lifestyle change [F = (4,230) = 3.27, p = 0.01]. But self-reported health status was not
associated with expecting a prescription or asking if there might be a prescription drug to
treat the patient/study participant (p < 0 .025).
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Table 21.
One-Way ANOVA for Prescription Request: Question 16, DTCA Help in Decision
Making
Sum of
Behavior
Expect RX

Might RX

Mention ad

Factor
Between groups

squares

Mean
df

square

1.188

4

.297

Within groups

55.255

227

.243

Total

56.444

231

3.686

4

.922

Within groups

50.875

225

.226

Total

54.561

229

2.662

4

.666

Within groups

22.728

228

.100

Total

25.391

232

3.125

4

.781
.748

Between groups

Between groups

Did Dr.

Between groups

give RX

Within groups

172.067

230

Total

175.191

234

F

Sig.

1.221

.303

4.075

.003*

6.677

.000*

1.044

.385

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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Table 22.
One-Way ANOVA for Prescription Request: Question 17, Health Status
Sum of
Behavior
Expect Rx

Might Rx

Mention ad

Factor
Between groups

squares

Mean
df

square

1.332

4

.333

Within groups

55.112

227

.243

Total

56.444

231

.660

4

.165

Within groups

53.901

225

.240

Total

54.561

229

1.740

4

.435

Within groups

23.651

228

.104

Total

25.391

232

9.436

4

2.359
.721

Between groups

Between groups

Did Dr.

Between groups

give Rx

Within groups

165.756

230

Total

175.191

234

F

Sig.

1.372

.245

.689

.600

4.193

.003*

3.273

.012*

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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As shown in Table 23, the number of hours per week spent using the Internet or
World Wide Web was associated with mentioning a prescription drug advertisement that
was seen or heard [F = (36, 191) = 1.6, p = 0.02]. Even so, no statistically significant
differences (p < 0 .025) were found between the number of hours per week using the
Internet or World Wide Web and the expectation for a prescription, asking whether there
might be a prescription drug to treat the patient/study participant, or for a doctor giving or
recommending a prescription.
Being a male patient/study participant was associated with going to a visit and not
expecting a doctor to prescribe a drug [F = (1,228) = 5.65, p = 0.02], as shown in Table
24. No statistically significant differences (p < 0 .025) were found for being male
patient/study participant and the expectation for a prescription, mentioning of an
advertisement, or to the doctor’s prescribing outcome.
Being married was associated with not mentioning a prescription drug
advertisement that was seen or heard [F = (4,226) = 4.11, p = 0.00], as shown in Table
25. Still, no statistically significant differences (p < 0 .025) were indicated between
marital status and a doctor giving a prescription, recommending a prescription,
recommending an over-the-counter drug, or recommending a behavior or lifestyle
change, the expectation for a prescription, or asking whether there might be a prescription
drug to treat the patient/study participant.
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Table 23.
One-Way ANOVA for Prescription Request: Question 18, Use of Internet or World Wide
Web
Sum of
Behavior
Expect Rx

Factor

squares

Mean
df

square

Between groups

11.318

36

.314

Within groups

44.083

190

.232

Total

55.401

226

7.393

36

.205

Within groups

46.189

188

.246

Total

53.582

224

5.690

36

.158

Within groups

18.872

191

.099

Total

24.561

227

Did Dr.

Between groups

33.271

37

.899

give Rx

Within groups

139.773

192

.728

Total

173.043

229

Might Rx

Mention ad

Between groups

Between groups

F

Sig.

1.355

.101

.836

.733

1.600

.024*

1.235

.182

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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Table 24.
One-Way ANOVA for Prescription Request: Question 19, Gender
Sum of
Behavior
Expect Rx

Might Rx

Mention ad

Factor
Between groups

squares

Mean
df

square

1.349

1

1.349

Within groups

54.412

228

.239

Total

55.761

229

.327

1

.327

Within groups

53.475

226

.237

Total

53.803

227

.039

1

.039

Within groups

24.567

229

.107

Total

24.606

230

1.134

1

1.134
.750

Between groups

Between groups

Did Dr.

Between groups

give Rx

Within groups

173.338

231

Total

174.472

232

F

Sig.

5.651

.018*

1.384

.241

3.64

.547

1.511

.220

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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Table 25.
One-Way ANOVA for Prescription Request: Question 20, Marital Status
Sum of
Behavior
Expect Rx

Might Rx

Mention ad

Factor

Mean

squares

df

square

.995

4

.249

Within groups

54.936

225

.244

Total

55.930

229

.605

4

.151

Within groups

53.431

223

.240

Total

54.035

227

1.721

4

.430

Within groups

23.638

226

.105

Total

25.359

230

6.945

4

1.736
.735

Between groups

Between groups

Between groups

Did Dr.

Between groups

give Rx

Within groups

167.527

228

Total

174.472

232

F

Sig.

1.018

.399

.631

.641

4.113

.003*

2.363

.054*

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. give Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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As shown in Table 26, no statistically significant differences (p < 0 .025) were
indicated between higher levels of education and asking whether there might be a
prescription drug to treat the patient/study participant, mentioning a prescription drug
advertisement that was seen or heard, or the expectation for a prescription or to the
doctor’s prescribing outcome. Likewise, as shown in Table 27, there were no statistically
significant differences (p < 0 .025) between race and the expectation for a prescription,
asking if there was a prescription drug for treatment, mentioning an advertisement that
was seen or heard, or the doctor’s response.
Summary
The purpose of this study was to determine if an association exists between
DTCA and health care seeking behaviors and to explore patient perspectives on the issue
as they relate to the overall health care experience. This study was quantitative and the
data were analyzed using descriptive statistics and ANOVA, which were employed to test
the hypotheses of this study. A two-step technique was used, as applicable, using SPSS,
Version 21. First, the independent variables and the dependent variable were loaded into
an ANOVA to determine the predictive power of the equation. Next, the applicable
sociodemographic variable(s) were loaded into an equation with the dependent variable
to assess their impact. Finally, the predictive power of the two equations was compared to
determine the predictive value of DTCA. All data analyses and statistical significance
were assessed at the p < 0.025 level, given the Bonferroni correction.
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Table 26.
One-Way ANOVA for Prescription Request: Question 21, Education
Sum of
Behavior
Expect Rx

Might Rx

Mention ad

Factor
Between groups

squares

Mean
df

square

2.527

6

.421

Within groups

53.577

224

.239

Total

56.104

230

3.221

6

.537

Within groups

50.963

222

.230

Total

54.183

228

1.544

6

.257

Within groups

23.831

225

.106

Total

25.375

231

5.337

6

.890
.748

Between groups

Between groups

Did Dr.

Between groups

do Rx

Within groups

169.825

227

Total

175.162

233

F

Sig.

1.761

.108

2.338

.033*

2.430

.027*

1.189

.313

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. do Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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Table 27.
One-Way ANOVA for Prescription Request: Question 23, Race
Sum of
Behavior
Expect Rx

Might Rx

Mention ad

Factor
Between groups

squares

Mean
df

square

.515

2

.258

Within groups

55.929

229

.244

Total

56.444

231

.662

2

.331

Within groups

53.899

227

.237

Total

54.561

229

.537

2

.269

Within groups

24.853

230

.108

Total

25.391

232

.810

2

.405
.752

Between groups

Between groups

Did Dr.

Between groups

do Rx

Within groups

174.381

232

Total

175.191

234

F

Sig.

1.055

.350

1.393

.250

2.485

.086

.539

.584

Note. Expect Rx, Might Rx, Meaningful, and Did Dr. do Rx correspond to survey
questions 10, 11, 12, and 13, respectively, as all survey questions are displayed in Table
2. Significance was assessed at the *p < 0.025 level.
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For Hypothesis 1, there was limited evidence that college-affiliated adult
patients/study participants who saw advertisements for prescription drugs were more
likely to (a) rate their doctor interactions higher; (b) talk to their doctor about a
prescription drug; and (c) have a recent visit to their doctor, nurse practitioner, or
physician’s assistant. Lower health status, being a man, being married, and lower
education levels were all associated with more office visits.
For Hypothesis 2, there was limited evidence that college-affiliated adult
patients/study participants who saw advertisements for prescription drugs or searched for
additional information about a prescription drug were more likely to (a) ask their doctor if
there was a prescription drug to treat them; (b) expect a doctor to prescribe a drug; (c)
have a doctor give them a prescription, recommend a prescription, recommend an overthe-counter drug, or recommend a behavior or lifestyle change; and (d) mention a
prescription drug to their doctor. Lower health status, the number of hours spent on the
Internet or World Wide Web per week, being a woman, being single, higher education
levels, and being an ethnic minority were all associated with requesting prescription
drugs. Chapter 5 includes an interpretation of the findings, discussion of the findings, the
limitations of the study, implications for social change, recommendations for future
study, and conclusions.
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Chapter 5: Discussion, Conclusions, and Recommendations
Summary
The purpose of this quantitative study was to determine if an association exists
between DTCA and health care-seeking behaviors. The theoretical framework consisted
of social learning theory, information integration theory, and prospect theory. The
research questions addressed in this study included identifying if exposure to DTCA (a)
is associated with physician office visits, (b) influences a patient/physician conversation
regarding a prescription, (c) influences requesting a prescription, and (d) has an impact
on patients’ ratings of the overall interaction with the physician. Data were derived from
an online survey adapted from an FDA study (HHS, 2004). Participants included 235
college-affiliated adults. Data were analyzed using descriptive statistics and ANOVAs.
The Bonferroni correction was used to control the family-wise Type I error rate.
According to study results, seeing advertisements for prescription drugs was associated
with a recent doctor visit, asking whether a prescription drug was available to treat a
condition, expecting to receive a prescription, receiving a prescription, and mentioning a
prescription drug to a doctor. Future researchers should consider a non-college-affiliated
sample and the post-implementation impact of the Affordable Care Act. Social change
implications of the study include better consumer education and protection, more
responsible health care policy and corporate decision making, and the potential
prevention of unnecessary drug- and health care-seeking behavior.
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Significance of the Study
The United States is ranked low on quality, efficiency, access, equity, and ability
for citizens to lead longer and healthier lives (McCarthy, 2014; Mathaisel & Comm,
2014). Pharmaceutical companies are viewed as one of several contributors to the
sustainability of the health care industry. Therefore, this study can provide information to
focus DTCA efforts to help improve availability, dependability, capability, affordability,
and marketability for prescription drugs. The increase in the use of DTCA by
pharmaceutical companies suggests that this practice is profitable. Given the potential
opportunity for positive or negative results, more assessments of DTCA are needed to
understand its impact. This study could help to address this gap in the literature and offer
opportunities for focusing further research in more appropriate areas.
This study could also provide greater insight into opportunities to mitigate the
potential impacts of DTCA. Overuse and inordinate cost burdens on patients are all
potential negative outcomes resulting from inappropriate DTCA. Additionally, physicians
feeling pressured to switch to new, more profitable medications may be another negative
outcome that this study can help to better understand. Understanding the impact of DTCA
will provide managers and executives, as well as governments and legislatures, with
information that can help to guide policy development, strategies, and health plan
decisions. Additional guidance can help to ensure that patients have adequate information
to make appropriate health care decisions.
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Assumptions
Several assumptions were made in this study. Among them are the following. It
was assumed that all participants responded truthfully to the survey and all participants
had access to the Internet or a computer. Additionally, I assumed that respondents to the
HHS (2004) survey, which was used for comparative purposes, answered the questions
honestly. It was also assumed that the established statistical methods employed in this
study were reliable and representative of the national population. Additionally, I assumed
that the influence of mass media on society (Bandura, 2001) is substantial and the
pharmaceutical industry is aggressive in nature (Angell, 2011).
Limitations
Several limitations must be acknowledged relative to this study. Generalizability
is limited because this study was open to only college-affiliated adults. Additionally, due
to the reliance upon the online university participant pool and SurveyMonkey,
participants had to have online access. In this sample of 235 participants, there was an
underrepresentation of many racial ethnic groups, with 80.5% of participants selfreporting as members of the White/Caucasian American category. Given the statistically
significant differences identified across sociodemographic characteristics, this disparity
could have affected the outcomes. Additionally, there may be differences relative to
ethnic minorities who were not discovered, given the small representation of this
population in this study. Overall, due to the nature of the survey—personal health—
respondents may not have been comfortable answering survey questions. Finally, college
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students are traditionally younger, more educated, and in other ways different from
members of society in general.
Interpretation of Findings
The association between DTCA and health care-seeking behaviors and patient
perspectives on the issue relative to the patient’s overall health care experience were
studied. SPSS was used to analyze data. All data analyses and statistical significance
were assessed at the p < 0.025 level. The following research questions were addressed in
detail and were the catalyst for this study:
1.

What is the relationship between direct-to-consumer advertising (DTCA)
and physician office visits?

2.

What is the relationship between direct-to-consumer advertising (DTCA)
and patients asking for a prescription?

These questions were researched through two hypotheses. Hypothesis 1 related to
physician office visits and exposure to DTCA:
H10: There is no relationship between patient exposure to DTCA and subsequent
physician office visits.
H1a: There is a direct association between patient exposure to DTCA and
subsequent physician office visits.
Hypothesis 2 related to request for a specific prescription medication and exposure to
DTCA:
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H20: There is no relationship between patient exposure to DTCA and a patient
asking subsequently for a corresponding prescription drug.
H2a: There is a direct association between patient exposure to DTCA and a
patient asking subsequently for a corresponding prescription drug.
For Hypothesis 1, there was limited evidence that college-affiliated adult study
participants who saw advertisements for prescription drugs were more likely to (a) rate
their doctor interactions higher; (b) talk to their doctor about a prescription drug; and (c)
have a recent visit to their doctor, nurse practitioner, or physician’s assistant. Lower
health status, being a man, being married, and lower education levels were all associated
with more office visits.
For Hypothesis 2, there was limited evidence that college-affiliated adult study
participants who saw advertisements for prescription drugs or searched for additional
information about a prescription drug were more likely to (a) ask their doctor if there was
a prescription drug to treat them; (b) expect a doctor to prescribe a drug; (c) have a doctor
give them a prescription, recommend a prescription, recommend an over-the-counter
drug, or recommend a behavior or lifestyle change; and (d) mention a prescription drug to
their doctor. Lower health status, the number of hours spent on the Internet or World
Wide Web per week, being a woman, being single, higher education levels, and being an
ethnic minority were all associated with requesting prescription drugs.
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Implications for Social Change
The United States and New Zealand are the only two industrialized nations that
permit DTCA, and pharmaceutical firms in these countries have the highest profit
margins of any industries in these two countries (Hawthorne, 2010). With increasingly
greater numbers—more than 50%—of all people in the United States taking prescription
drugs, the total annual retail sales of prescription drugs exceeding $300 billion a year, and
more than $28 million being spent by PhRMA to lobby members of Congress, it is
difficult for the FDA to ensure consumer protection (PhRMA, 2011). The significant
societal dependency on prescription drugs provides a potentially endless supply of
individuals who are vulnerable to abuse. Deadly side effects and contraindications are but
a few of the many dangers associated with prescription drugs. Additionally, the principalagent relationship between consumers and physicians provides an example of the
potential patient vulnerabilities.
The most significant findings of this study are that DTCA is associated with
patients asking more questions, having more office visits and patients having a lower
overall health status. As DTCA is associated with patients asking their physicians more
questions, this increased communication could help patients make better decisions about
the potential risks, benefits and costs of prescription drugs. As patients, especially those
who perceive themselves as less healthy, attempt to understand the very complex issues
around their health care, asking questions can help.
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Given that DTCA is associated with more office visit, physicians can help
patients to better understand this tendency as well as the positive or negative impacts.
Physicians are trained to help patients make informed decisions about their health care.
Being aware of the DTCA and office visits association can help physicians assist patients
in taking better care of themselves, minimizing unnecessary office visits, and reducing
their out of pocket costs.
Evidence from this study also suggests a strong association between DTCA and
patients with a lower health status. Knowledge of this association can help patients and
physicians to focus their efforts on ensuring a positive social impact. Awareness of this
relationship can change patient, physician and healthcare policy maker decision making
and reduce the likelihood of adverse clinical and financial implications. This could
provide a significant opportunity to help the least healthy of society to greatly improve
their health, quality of life and ability to return to work if they have been hindered by
their poor health status.
Additionally, health care policy has a financial impact and drives corporate and
individual decisions and behavior. This study provides a clearer understanding of what
aspects of DTCA should be carefully considered in the development of local and national
health care policy. This understanding will reduce the probability of unintended negative
consequences from legislation and policy.
Other social change implications of this study include consumer protection in a
risky market and the prevention of unnecessary and expensive drug- and health care
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seeking-behavior. The discovered link between the advertising component of marketing
campaigns and health care-seeking behavior can potentially drive an overuse of
unnecessary medications and a subsequent unnecessary reduction in health status and
added cost burden for patients. FDA guidance and regulations, federal and state health
care policy, and patient interaction with health care professionals are all documented
factors that may be touched by DTCA. As a result, it is important to understand the
impact of DTCA because it can be used to improve the health status and economic
prosperity of society. This knowledge can also be used to better manage the potential for
abuse, given the industry financial incentives. Using the identified significant aspects of
DTCA, physicians have a better understanding of the aspects of DTCA that impact
patient decision making. Having this information could help physicians to develop more
effective ways of communicating with patients and developing more effective care plans.
Recommendations for Further Study
Future researchers can address the limitations of this study by investigating a
larger sample size that is not limited by Internet access, college affiliation, or age.
Although the type of medium used in this study was not restrictive geographically,
cultural and geographic preferences and differences may still have existed.
This study focused on participants associated with an academic community. A
study that collects information regarding students’ major and current occupation might
also provide additional insights regarding attitudes and behaviors relative to DTCA.
Behaviors and attitudes may vary depending upon type of occupation, medical
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experience, and training. As an example, undergraduate nursing students may provide
different answers than undergraduate business students. The degree to which patients
truly comprehend and understand the information in DTCA could provide an additional
research opportunity. Finally, an assessment of how much information patients retain
from DTCA and whether that retention is tempered or enhanced by health status or the
length of the patient-physician relationship. Further research may reveal that different
degrees of retention exist for patients with severe conditions such as terminal cancer, and
patients with other conditions such as a minor cold. Additional research may also reveal
that the length of an established physician-patient relationship may mitigate the impact of
DTCA.
Quantifying the financial impact of DTCA could provide insight into corporate
incentives. Research that better clarifies the incentives and disincentives for
pharmaceutical companies could help to drive safer corporate decisions and potentially
influence health care policy. Research in this area could help to ensure that corporate
incentives are aligned with desired positive patient outcomes.
The FDA study (HHS, 2004) was one of the initial studies to focus on the doctorpatient relationship and its broad implications for health care. The OPDP continues
research projects on this topic, with current studies including an examination of online
DTC drug promotion, experimental study of format variations in the brief summary of
DTC print advertisements, and health care professional survey of prescription drug
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promotion. With students as participants, this study provided information that could
enhance the overall patient care experience.
Finally, given the full implementation of the unprecedented employer, health care
industry, and individual changes required under the Affordable Care Act, future research
may produce different results. Signed into law by President Barack Obama in 2010, the
Affordable Care Act seeks to improve access to the U.S. health care system and increases
individual responsibility as it relates to a persons’ health care. Once fully implemented in
the coming years, employer requirements to provide coverage for older children,
individual mandates to obtain coverage or be subjected to a penalty, and health care
industry performance requirements for payment could likely produce different research
findings and opportunities. Future research could also help with the assessment of the
impact of the Affordable Care Act.
Concluding Remarks
A few of the hypothesized associations were not supported quantitatively, so this
study can contribute to the development of new knowledge by specifying the aspects of
DTCA that are associated with patient behaviors and perceptions. The findings of this
study outline the specific models that more clearly explain the impact of DTCA. Social
change implications of the study include consumer protection in a risky market and the
prevention of unnecessary, expensive, and potentially dangerous drug- and health careseeking behaviors.
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Appendix A: Direct-to-Consumer (DTC) Promotion of Prescription Drugs Survey
1. How long has it been since the last time you saw a doctor, a nurse practitioner, or a
physician’s assistant where you talked about a health condition or concern of your own,
not for a child or parent or someone else?
Within the last week
1 to 4 weeks ago
5 weeks to 3 months ago
4 to 6 months ago
7 to 11 months ago
1 year ago
More than 1 year ago
Never
2. Was this a routine visit, such as a checkup or physical?
Yes
No
Don’t know
3. In the last year, do you recall seeing or hearing any advertisements for prescription
drugs?
Yes
No
4. Have you seen or heard any ads for prescription drugs in any of the following ways:
(check all that apply)
a. On television
b. On the radio
c. In a magazine
d. In a newspaper
e. On the Internet
f. In a letter, flyer or announcement you got in the mail
g. On an outdoor billboard
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h. In a grocery store or pharmacy
i. Anywhere else? (please specify)
5. In the last year, how many different prescription drugs do you recall seeing advertised
in any form?
None
One
Two
Three
Four
Five
Six
Seven
Eight
Nine
Ten
More than ten
6. Thinking about the ads you have seen both in print and on television, has an
advertisement for a prescription drug ever caused you to look for more information, for
example, about the drug or about your health?
Yes
No
7. What information did you look for?
Side effects
Interactions with other drugs/medicines
Dangers of the drug
Cost of the drug
Other (please specify)
8. Has an advertisement for a prescription drug ever caused you to ask a doctor about a
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medical condition or illness of your own that you had not talked to a doctor about before?
Yes
No
9. At any of the visits to your doctor, did you talk about a prescription drug?
Yes
No
10. Did you go to this visit expecting your doctor to prescribe a drug for you?
Yes
No
11. At that visit, did you ask whether there might be a prescription drug to treat you?
Yes
No
12. Did you mention an advertisement you saw or heard for a drug or bring information
about the advertised drug with you?
Yes, I mentioned an ad I saw or heard
Yes, I brought something about the drug with me
Yes, both
No
13. Did your doctor do one or more of the following: [Select all that apply]
Give you the prescription drug you asked about
Not give you the prescription drug you asked about
Recommend a different prescription drug
Recommend an over-the-counter drug
Recommend no drug
Recommend that you make changes in your behavior or lifestyle
Something else (please specify)
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14. Overall, how would you rate your interaction with your doctor at this visit?
Excellent
Good
Only fair
Poor
15. I like seeing advertisements for prescription drugs.
Agree Strongly
Agree Somewhat
Neither Agree nor Disagree
Disagree Somewhat
Disagree Strongly
16. Advertisements for prescription drugs help me make better decisions about my
health.
Agree Strongly
Agree Somewhat
Neither Agree nor Disagree
Disagree Somewhat
Disagree Strongly
17. Overall, would you say your health is:
Excellent
Very good
Good
Fair
Poor
18. How many hours in a typical week do you use the internet or world wide web at
home and at work?
Do not have a computer
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Number of hours?
19. Gender
Male
Female
20. What is your marital status? Are you:
Married
Single
Widowed
Divorced
Separated
21. What is the last grade of school that you completed?
Grade school or less
Some high school
Completed high school
Some college
Completed college
Graduate school or more
Other beyond high school (business, technical, etc.)
22. Are you of Hispanic, Latino, or Spanish origin?
No, not of Hispanic, Latino, or Spanish origin
Yes, Mexican, Mexican American, Chicano
Yes, Puerto Rican
Yes, Cuban
Yes, another Hispanic, Latino, or Spanish origin
Please state origin, for example Argentinean, Colombian, Dominican, Nicaraguan,
Salvadoran, or Other.
23. What is your race? Select one or more
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White
Black, African American, or Negro
American Indian or Alaska Native
Asian Indian
Chinese
Filipino
Japanese
Korean
Vietnamese
Native Hawaiian
Guamanian or Chamorro
Samoan
Other Asian, Other Pacific Islander, or Other Race – (For example Laotian, Thai,
Pakistani, Cambodian, Fijian, Tongan, or other)

24. What year were you born?

Survey adapted Patient and Physician Attitudes and Behaviors Associated with DTC
Promotion of Prescription Drugs, from U.S. Department of Health And Human Services,
Federal Drug Administration, 2004. Retrieved May 1, 2009, from http://www.fda.gov.
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Appendix B: Direct-to-Consumer Advertising and Patient
Healthcare Behaviors Consent Form (Participant Pool)
You are invited to participate in a study of direct-to-consumer drug advertising
(DTCA) and health care behaviors that you may have experienced in the last 12 months
of your adult life. You are selected as a potential participant in this study because you are
an adult and you are available through the Walden Participating Pool website voluntarily.
I ask that you read this form and ask any question you may have before agreeing to be in
the study. This study is being conducted by Patricia Kennedy-Tucker, a doctoral
candidate at Walden University.
Background information: The purpose of this study is to gain an understanding
of DTCA and health care behaviors and to explore patient perspectives on the issue as
they relate to the overall health care experience.
Procedures: If you agree to participate in this study, please read this informed
consent form and go ahead to respond to the survey questions. I will ask you to complete
the demographic questions at the end of the survey. There are a total of 23 questions and
you should be able to complete the survey in 5-8 minutes.
Confidentiality: The survey is anonymous. The records of this study will be kept
private. The research records will be kept in encrypted form.
Voluntary nature of the study: Your participation in the study is voluntary and
you are free to withdraw at any time during the process of completing the survey. Your
decision to participate in this study will not affect your relationship with your school or
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employer in any way. If you decide to withdraw your participation you may do so
without affecting your relationship with your current schooling or employment.
Risks and benefits of being in the study: There are no physical risks and no
benefits due to participating in the study. However, the proposed study may provide
social change implications to include consumer protection in a risky market and
prevention of unnecessary and expensive drug and health care seeking behavior.
Participants are not obligated to complete any part of the survey with which they are not
comfortable.
Contacts and questions: The researcher conducting this study is Patricia
Kennedy-Tucker. The university IRB may be contacted by e-mail at IRB@waldenu.edu
if you have any question about your right as participants.
Statement of consent: I have read the above information. I have asked any
necessary questions and received answers. I consent to participate in the study.
In order to protect your privacy, signature is not being collected and your completion of
survey would indicate your consent if you choose to participate. You may keep or print a
copy of the consent form for your record.
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Appendix C: Direct-to-Consumer (DTC) Advertising of Prescription Drugs
Informed Consent
You are invited to participate in a study of direct-to-consumer drug advertising
(DTCA) and health care behaviors that you may have experienced in the last 12 months
of your adult life. You are selected as a potential participant in this study because you are
an adult and your student status. I ask that you read this form and ask any question you
may have before agreeing to be in the study. This study is being conducted by Patricia
Kennedy-Tucker, a doctoral candidate at Walden University.
Background information: The purpose of this study is to gain an understanding
of DTCA and health care behaviors and to explore patient perspectives on the issue as
related to the overall health care experience.
Procedures: If you agree to participate in this study, please read this informed
consent form and go ahead to respond to the survey questions. There are a total of 24
questions and you should be able to complete the survey in 5-8 minutes.
Confidentiality: The survey is anonymous. The records of this study will be kept
private. The research records will be kept in encrypted form.
Voluntary nature of the study: Your participation in the study is voluntary and
you are free to withdraw at any time during the process of completing the survey. Your
decision to participate in this study will not affect your relationship with your school or
employer in any way.
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Risks and benefits of being in the study: There are no physical risks and no
benefits due to participating in the study. However, the proposed study may provide
social change implications to include consumer protection in a risky market and
prevention of unnecessary and expensive drug- and health care-seeking behavior.
Participants are not obligated to complete any part of the survey with which they are not
comfortable.
Payment: No payment, thank you gifts, or reimbursements are provided by the
researcher to participants.
Contacts and questions: The researcher conducting this study is Patricia
Kennedy-Tucker. The university IRB may be contacted by e-mail at IRB@waldenu.edu
if you have any question about your right as participants. Walden University’s approval
number for this study is 05-21-13-0019798 and it expires on May 20, 2014.
Results: If you would like to obtain a copy of the results of this study, please
contact the researcher at the above e-mail.
Statement of consent: I have read the above information. I have asked any
necessary questions and received answers. I consent to participate in the study. In order to
protect your privacy, signature is not being collected and your completion of survey
would indicate your consent if you choose to participate. You may keep or print a copy of
the consent form for your records.
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Appendix D: Institutional Review Board (IRB) Approval Form

Dear Ms. Kennedy-Tucker,
This e-mail is to notify you that the Institutional Review Board (IRB) has
approved your application for the study entitled, Exploring the Effects of Direct-toConsumer Advertising of Drugs on Patients’ Health Care-Seeking Behavior
Your approval # is 05-21-13-0019798. You will need to reference this number in
your doctoral study and in any future funding or publication submissions. Also attached
to this e-mail is the IRB approved consent form. Please note, if this is already in an online format, you will need to update that consent document to include the IRB approval
number and expiration date.
Your IRB approval expires on May 20, 2014. One month before this expiration
date, you will be sent a Continuing Review Form, which must be submitted if you wish to
collect data beyond the approval expiration date.
Your IRB approval is contingent upon your adherence to the exact procedures
described in the final version of the IRB application document that has been submitted as
of this date. If you need to make any changes to your research staff or procedures, you
must obtain IRB approval by submitting the IRB Request for Change in Procedures
Form. You will receive confirmation with a status update of the request within 1 week of
submitting the change request form and are not permitted to implement changes prior to
receiving approval. Please note that Walden University does not accept responsibility or
liability for research activities conducted without the IRB's approval, and the University
will not accept or grant credit for student work that fails to comply with the policies and
procedures related to ethical standards in research.
When you submitted your IRB application, you made a commitment to
communicate both discrete adverse events and general problems to the IRB within 1
week of their occurrence/realization. Failure to do so may result in invalidation of data,
loss of academic credit, and/or loss of legal protections otherwise available to the
researcher.
Both the Adverse Event Reporting form and Request for Change in Procedures
form can be obtained at the IRB section of the Walden web site or by e-mailing
irb@waldenu.edu:
http://researchcenter.waldenu.edu/Application-and-General-Materials.htm
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Researchers are expected to keep detailed records of their research activities (i.e.,
participant log sheets, completed consent forms, etc.) for the same period of time they
retain the original data. If, in the future, you require copies of the originally submitted
IRB materials, you may request them from Institutional Review Board.
Please note that this letter indicates that the IRB has approved your research. You
may not begin the research phase of your dissertation, however, until you have received
the Notification of Approval to Conduct Research e-mail. Once you have received this
notification by e-mail, you may begin your data collection.
Both students and faculty are invited to provide feedback on this IRB experience
at the link below:
http://www.surveymonkey.com/s.aspx?sm=qHBJzkJMUx43pZegKlmdiQ_3d_3d
Sincerely,
Jenny Sherer, M.Ed., CIP
Associate Director
Office of Research Ethics and Compliance
E-mail: irb@waldenu.edu
Fax: 626-605-0472
Phone: 612-312-1341
Office address for Walden University:
100 Washington Avenue South
Suite 900
Minneapolis, MN 55401
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